Search Result

Targets Recommended:	Adrenergic Receptor Target Protein Ligand-Linker Conjugate E3 Ligase Ligand-Linker Conjugate Ligand for Target Protein for PROTAC Ligand for E3 Ligase PD-1/PD-L1

Results for "Adrenergic Ligand Sets Inhibitors" in MCE Product Catalog:

By Targets:	Adrenergic Receptor (156) E3 Ligase Ligand-Linker Conjugate (136) Ligand for E3 Ligase (44) Ligand for Target Protein for PROTAC (41) PD-1/PD-L1 (2) Target Protein Ligand-Linker Conjugate (8) 5-HT Receptor (26) ADC Cytotoxin (1) ADC Linker (1) Adenosine Receptor (2) Adiponectin Receptor (1) Aldehyde Dehydrogenase (ALDH) (1) ALK (2) Amyloid-β (3) Androgen Receptor (4) Antibiotic (8) Antifolate (1) APC (1) Apoptosis (17) Aryl Hydrocarbon Receptor (2) ATM/ATR (1) ATP Citrate Lyase (1) ATP Synthase (1) Autophagy (18) Bacterial (9) Bcl-2 Family (5) Bcr-Abl (14) Bradykinin Receptor (1) Btk (2) Calcium Channel (4) CaMK (1) Cannabinoid Receptor (2) Casein Kinase (2) Caspase (1) CCR (1) CDK (7) CMV (2) CRFR (2) CXCR (4) Cytochrome P450 (3) Discoidin Domain Receptor (1) DNA/RNA Synthesis (3) Dopamine Receptor (19) Drug-Linker Conjugates for ADC (2) DYRK (2) E1/E2/E3 Enzyme (4) EBI2/GPR183 (1) EGFR (2) Endogenous Metabolite (16) Ephrin Receptor (1) Epigenetic Reader Domain (13) Estrogen Receptor/ERR (14) Factor Xa (1) FAK (2) Ferroptosis (2) FKBP (12) FLT3 (1) Fungal (1) G-quadruplex (3) GABA Receptor (8) GHSR (2) Glucosidase (1) GLUT (1) GNRH Receptor (2) GPR119 (1) GPR120 (1) GPR40 (2) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (7) Histone Methyltransferase (13) HIV (5) HSP (2) IAP (1) iGluR (5) Influenza Virus (3) Integrin (10) Interleukin Related (4) IRE1 (1) Lipoxygenase (1) LPL Receptor (1) LXR (1) mAChR (3) MCHR1 (GPR24) (5) MDM-2/p53 (4) MEK (2) Melatonin Receptor (1) Microtubule/Tubulin (1) Mitophagy (4) MMP (3) Monoamine Oxidase (1) Motilin Receptor (1) nAChR (3) Neurokinin Receptor (2) Neuropeptide Y Receptor (2) Neurotensin Receptor (2) NF-κB (2) Notch (2) Opioid Receptor (7) Oxytocin Receptor (2) P-glycoprotein (1) P2X Receptor (1) p38 MAPK (1) Parasite (2) PARP (1) Phosphatase (3) PKA (1) PKC (1) Potassium Channel (2) PPAR (6) Prostaglandin Receptor (1) PROTAC (37) PROTAC Linker (15) RAR/RXR (2) Reverse Transcriptase (2) ROR (3) SARS-CoV (1) Ser/Thr Protease (1) Sigma Receptor (10) Sirtuin (1) SNIPER (19) Sodium Channel (4) STAT (2) STING (2) Telomerase (1) Thrombin (1) TNF Receptor (2) Toll-like Receptor (TLR) (2) TRP Channel (2) Urotensin Receptor (5) VD/VDR (7) VEGFR (2) Virus Protease (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (405) Cardiovascular Disease (77) Endocrinology (147) Infection (25) Inflammation/Immunology (66) Metabolic Disease (42) Neurological Disease (141)

By Targets:

Adrenergic Receptor (156)

E3 Ligase Ligand-Linker Conjugate (136)

Ligand for E3 Ligase (44)

Ligand for Target Protein for PROTAC (41)

PD-1/PD-L1 (2)

Target Protein Ligand-Linker Conjugate (8)

5-HT Receptor (26)

ADC Cytotoxin (1)

ADC Linker (1)

Adenosine Receptor (2)

Adiponectin Receptor (1)

Aldehyde Dehydrogenase (ALDH) (1)

ALK (2)

Amyloid-β (3)

Androgen Receptor (4)

Antibiotic (8)

Antifolate (1)

APC (1)

Apoptosis (17)

Aryl Hydrocarbon Receptor (2)

ATM/ATR (1)

ATP Citrate Lyase (1)

ATP Synthase (1)

Autophagy (18)

Bacterial (9)

Bcl-2 Family (5)

Bcr-Abl (14)

Bradykinin Receptor (1)

Btk (2)

Calcium Channel (4)

CaMK (1)

Cannabinoid Receptor (2)

Casein Kinase (2)

Caspase (1)

CCR (1)

CDK (7)

CMV (2)

CRFR (2)

CXCR (4)

Cytochrome P450 (3)

Discoidin Domain Receptor (1)

DNA/RNA Synthesis (3)

Dopamine Receptor (19)

Drug-Linker Conjugates for ADC (2)

DYRK (2)

E1/E2/E3 Enzyme (4)

EBI2/GPR183 (1)

EGFR (2)

Endogenous Metabolite (16)

Ephrin Receptor (1)

Epigenetic Reader Domain (13)

Estrogen Receptor/ERR (14)

Factor Xa (1)

FAK (2)

Ferroptosis (2)

FKBP (12)

FLT3 (1)

Fungal (1)

G-quadruplex (3)

GABA Receptor (8)

GHSR (2)

Glucosidase (1)

GLUT (1)

GNRH Receptor (2)

GPR119 (1)

GPR120 (1)

GPR40 (2)

HIF/HIF Prolyl-Hydroxylase (2)

Histamine Receptor (7)

Histone Methyltransferase (13)

HIV (5)

HSP (2)

IAP (1)

iGluR (5)

Influenza Virus (3)

Integrin (10)

Interleukin Related (4)

IRE1 (1)

Lipoxygenase (1)

LPL Receptor (1)

LXR (1)

mAChR (3)

MCHR1 (GPR24) (5)

MDM-2/p53 (4)

MEK (2)

Melatonin Receptor (1)

Microtubule/Tubulin (1)

Mitophagy (4)

MMP (3)

Monoamine Oxidase (1)

Motilin Receptor (1)

nAChR (3)

Neurokinin Receptor (2)

Neuropeptide Y Receptor (2)

Neurotensin Receptor (2)

NF-κB (2)

Notch (2)

Opioid Receptor (7)

Oxytocin Receptor (2)

P-glycoprotein (1)

P2X Receptor (1)

p38 MAPK (1)

Parasite (2)

PARP (1)

Phosphatase (3)

PKA (1)

PKC (1)

Potassium Channel (2)

PPAR (6)

Prostaglandin Receptor (1)

PROTAC (37)

PROTAC Linker (15)

RAR/RXR (2)

Reverse Transcriptase (2)

ROR (3)

SARS-CoV (1)

Ser/Thr Protease (1)

Sigma Receptor (10)

Sirtuin (1)

SNIPER (19)

Sodium Channel (4)

STAT (2)

STING (2)

Telomerase (1)

Thrombin (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (2)

TRP Channel (2)

Urotensin Receptor (5)

VD/VDR (7)

VEGFR (2)

Virus Protease (1)

Wnt (2)

β-catenin (1)

By Research Areas:

Cancer (405)

Cardiovascular Disease (77)

Endocrinology (147)

Infection (25)

Inflammation/Immunology (66)

Metabolic Disease (42)

Neurological Disease (141)

725

Inhibitors & Agonists

Screening Libraries

Dye Reagents

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas

HY-133045

*VHL Ligand* 8**	Ligand for E3 Ligase	Cancer
VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM.

HY-126534

*CDK ligand* for PROTAC**	CDK Ligand for Target Protein for PROTAC	Cancer
CDK ligand for PROTAC is a CDK inhibitor with antitumor activity. CDK ligand for PROTAC and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.

HY-126534A

*CDK ligand* for PROTAC hydrochloride**	CDK Ligand for Target Protein for PROTAC	Cancer
CDK ligand for PROTAC hydrochloride is a CDK inhibitor with antitumor activity. CDK ligand for PROTAC hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.

HY-126456

(S,R,S)-AHPC-propargyl VH032-propargyl; VHL Ligand 7	Ligand for E3 Ligase	Cancer
(S,R,S)-AHPC-propargyl (VH032-propargyl) is a VHL ligand which is used in “click reaction” for PROTACs.

HY-133073

*CCR7 Ligand* 1** CCR7-Cmp2105	CCR Ligand for Target Protein for PROTAC	Cancer
CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a K_d of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC₅₀ of 7.3 μM.

HY-P1840A

*Galanin Receptor Ligand* M35 TFA**	Neuropeptide Y Receptor	Endocrinology Neurological Disease
Galanin Receptor Ligand M35 TFA is a high-affinity ligand and antagonist of galanin receptor (K_d=0.1 nM). Galanin Receptor Ligand M35 TFA exerts a K_i values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.

HY-P1840

*Galanin Receptor Ligand* M35**	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Galanin Receptor Ligand M35 is a high-affinity ligand and antagonist of galanin receptor (K_d=0.1 nM). Galanin Receptor Ligand M35 exerts a K_i values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.

HY-133046

*VHL Ligand-Linker Conjugates 17*	E3 Ligase Ligand-Linker Conjugate	Cancer
VHL Ligand-Linker Conjugates 17 incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 17 can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 is a highly potent androgen receptor (AR) PROTAC degrader.

HY-128808

*cIAP1 ligand* 1** E3 ligase Ligand 12	Ligand for E3 Ligase	Cancer
cIAP1 ligand 1 is the LCL161 derivative based IAP ligand. cIAP1 ligand 1 can be connected to the ABL ligand for protein by a linker to form SNIPER.

HY-128809

*cIAP1 ligand* 2** E3 ligase Ligand 11	Ligand for E3 Ligase	Cancer
cIAP1 ligand 2 is the LCL161 derivative based IAP ligand. cIAP1 ligand 2 can be connected to the ABL ligand for protein by a linker to form SNIPER.

HY-103597

Thalidomide-O-COOH Cereblon Ligand 3; E3 ligase Ligand 3	Ligand for E3 Ligase	Others
Thalidomide-O-COOH (Cereblon ligand 3) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.

HY-103596

Thalidomide-4-OH Cereblon Ligand 2; E3 ligase Ligand 2	Ligand for E3 Ligase	Cancer
Thalidomide-4-OH (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) can be connected to the ligand for protein by a linker to form PROTACs.

HY-128837

Nutlin carboxylic acid MDM2 Ligand 1; E3 ligase Ligand 16	Ligand for E3 Ligase	Cancer
Nutlin carboxylic acid (MDM2 ligand 1) is the Nutlin 3-based MDM2 ligand. Nutlin carboxylic acid (MDM2 ligand 1) can be connected to the ligand for protein by a linker to form PROTACs.

HY-128380

Dibenamine hydrochloride N-(2-Chloroethyl)dibenzylamine hydrochloride	Adrenergic Receptor	Metabolic Disease
Dibenamine hydrochloride is a competitive and irreversible adrenergic blocking agent and is known to modify the pharmacological effects of epinephrine. Dibenamine hydrochloride cause a significant increase in the rate of destruction of I-epinephrine in the mouse.

HY-114399

STING ligand-1
STING Inflammation/Immunology

STING ligand-1 is a lead STING ligand with an IC₅₀ of 68 nM for HAQ STING.

*STING ligand-1*	STING	Inflammation/Immunology
STING ligand-1 is a lead STING ligand with an IC₅₀ of 68 nM for HAQ STING.

HY-128807

*E3 ligase Ligand* 10**	Ligand for E3 Ligase	Cancer
E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-129653

*E3 ligase Ligand* 18**	Ligand for E3 Ligase	Cancer
E3 ligase Ligand 18 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 18 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-128811

*E3 ligase Ligand* 14**	Ligand for E3 Ligase	Cancer
E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-43961

*E3 ligase Ligand* 8**	Ligand for E3 Ligase	Cancer
E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-128810

*E3 ligase Ligand* 13**	Ligand for E3 Ligase	Cancer
E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-128806

*E3 ligase Ligand* 9**	Ligand for E3 Ligase	Cancer
E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-41547

Thalidomide 4-fluoride Cereblon Ligand 4; E3 ligase Ligand 4	Ligand for E3 Ligase	Cancer
Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966).

HY-U00439

Protein kinase inhibitors 1
DYRK Cancer

Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC₅₀ of 74 nM and K_d of 9.5 nM.

*Protein kinase inhibitors* 1**	DYRK	Cancer
Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC₅₀ of 74 nM and K_d of 9.5 nM.

HY-103200

SR59230A hydrochloride	Adrenergic Receptor	Metabolic Disease Cardiovascular Disease
SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC₅₀s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.

HY-100672

SR59230A	Adrenergic Receptor	Metabolic Disease Cardiovascular Disease
SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC₅₀s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.

HY-B0098S

Doxazosin D8 UK 33274 D8	Adrenergic Receptor	Endocrinology Cardiovascular Disease
Doxazosin D8 (UK 33274 D8) is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1 adrenergic receptors.

HY-130245

*PCSK9 ligand* 1**	Ser/Thr Protease	Metabolic Disease
PCSK9 ligand 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a K_i of 107 nM. PCSK9 ligand 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor.

HY-125905

VH032-cyclopropane-F VHL Ligand 3; E3 ligase Ligand 19	Ligand for E3 Ligase	Cancer
VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4。

HY-111823

VH032 thiol
VHL Ligand 6
Ligand for E3 Ligase Cancer

VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC.

VH032 thiol VHL Ligand 6	Ligand for E3 Ligase	Cancer
VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC.

HY-101626

*Sigma-LIGAND-1*	Sigma Receptor	Neurological Disease
Sigma-LIGAND-1 is a selective sigma receptor ligand, has receptor IC₅₀s of 16 nM at the DTG site, 19 nM at the PPP site, and a K_i of 4000 nM at the dopamine D2 receptor.

HY-129967

*PROTAC IRAK4 ligand-1*	Ligand for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966).

HY-U00126

5HT6-ligand-1
5-HT Receptor Neurological Disease

5HT6-ligand-1 is a potent 5-HT6 receptor ligand with a K_i of 1.43 nM.

*5HT6-ligand-1*	5-HT Receptor	Neurological Disease
5HT6-ligand-1 is a potent 5-HT6 receptor ligand with a K_i of 1.43 nM.

HY-128836

(4R,5S)-Nutlin carboxylic acid MDM2 Ligand 2; E3 ligase Ligand 15	Ligand for E3 Ligase	Cancer
(4R,5S)-Nutlin carboxylic acid (MDM2 ligand 2) is the Nutlin 3-based MDM2 ligand. (4R,5S)-Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTACs.

HY-126351

*PROTAC ERRα ligand* 2**	Estrogen Receptor/ERR	Cancer
PROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist with an IC₅₀ of 5.67 nM. PROTAC ERRα ligand 2 (IC₅₀=5.67 nM) displays a ~11-fold improved potency than XCT790 (IC₅₀=61.3 nM).

HY-129939

*PROTAC BRD4 ligand-1*	Epigenetic Reader Domain Ligand for Target Protein for PROTAC	Cancer
PROTAC BRD4 ligand-1 is a potent BET inhibitor and a ligand for target BRD4 protein for PROTACT GNE-987 (HY-129937A).

HY-111845

Estrone-N-O-C1-amido ERα Ligand 1	Estrogen Receptor/ERR Ligand for Target Protein for PROTAC	Cancer
Estrone-N-O-C1-amido (ERα ligand 1) is an Estrone-based estrogen ligand, which targets estrogen receptor α (ERα). Estrone-N-O-C1-amido (ERα ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER.

HY-111839

ATRA-hydroxyimino CRABP-II Ligand 1	Ligand for Target Protein for PROTAC	Cancer
ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells.

HY-130297

*PROTAC BCR-ABL1 ligand* 1**	Bcr-Abl	Cancer
PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1.

HY-130296

Palbociclib-propargyl PROTAC CDK6 Ligand 1	Ligand for Target Protein for PROTAC	Cancer
Palbociclib-propargyl is a ligand for target protein CDK6 for PROTAC, and binds to CRBN ligand via a PEG linker to make a PROTAC CP-10. CP-10 shows a DC₅₀ of 2.1 nM for CDK6.

HY-111843

Ch55-O-C3-NH2 RAR Ligand 1	RAR/RXR Ligand for Target Protein for PROTAC Autophagy	Cancer
Ch55-O-C3-NH2 (RAR ligand 1) is a Ch 55-based ligand, which targets RAR. Ch55-O-C3-NH2 (RAR ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER.

HY-U00425

*PROTAC ERRα ligand* 1**	Estrogen Receptor/ERR	Cancer
PROTAC ERRα ligand 1 is an estrogen-related receptor α (ERRα) antagonist with IC₅₀s of 0.04 and 2.8 μM for ERRα and ERRγ, respectively.

HY-136306

*Metallo β-lactamase ligand* 1**	Bacterial	Infection
Metallo-beta-lactamase ligand 1 is a class B β-lactamase inhibitor with antibacterial activity extracted from patent WO2019221122A1, compound A.

HY-130270

*AhR Ligand-Linker Conjugates 1* E3 Ligase Ligand-Linker Conjugates 57	E3 Ligase Ligand-Linker Conjugate	Cancer
AhR Ligand-Linker Conjugates 1 (E3 Ligase Ligand-Linker Conjugates 57) incorporates an IAP ligand for the E3 ubiquitin ligase, and a SNIPER linker. AhR Ligand-Linker Conjugates 1 can be used to design SNIPER.

HY-125906

*VHL Ligand-Linker Conjugates 15* E3 Ligase Ligand-Linker Conjugates 56	E3 Ligase Ligand-Linker Conjugate	Cancer
VHL Ligand-Linker Conjugates 15 incorporates an VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 15 can be used to design PROTACs.

HY-44012

*SMARCA-BD ligand* 1 for Protac**	Ligand for Target Protein for PROTAC	Cancer
SMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.

HY-44012A

*SMARCA-BD ligand* 1 for Protac dihydrochloride**	Ligand for Target Protein for PROTAC	Cancer
SMARCA-BD ligand 1 for Protac dihydrochloride is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.

HY-128822

*cIAP1 Ligand-Linker Conjugates 13* E3 ligase Ligand-Linker Conjugates 43	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 13 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 13 can be used to design SNIPERs.

HY-128815

*cIAP1 Ligand-Linker Conjugates 14* E3 ligase Ligand-Linker Conjugates 36	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 14 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 14 can be used to design SNIPERs.

HY-128820

*cIAP1 Ligand-Linker Conjugates 1* E3 ligase Ligand-Linker Conjugates 41	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 1 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 1 can be used to design SNIPERs.

HY-128819

*cIAP1 Ligand-Linker Conjugates 3* E3 ligase Ligand-Linker Conjugates 40	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 3 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 3 can be used to design SNIPERs.

HY-128826

*cIAP1 Ligand-Linker Conjugates 10* E3 ligase Ligand-Linker Conjugates 47	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 10 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 10 can be used to design SNIPERs.

HY-128813

*cIAP1 Ligand-Linker Conjugates 15* E3 ligase Ligand-Linker Conjugates 34	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 15 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 can be used to design SNIPERs.

HY-128824

*cIAP1 Ligand-Linker Conjugates 9* E3 ligase Ligand-Linker Conjugates 45	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 9 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 9 can be used to design SNIPERs.

HY-128812

*cIAP1 Ligand-Linker Conjugates 11* E3 ligase Ligand-Linker Conjugates 33	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 11 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 can be used to design SNIPERs.

HY-128817

*cIAP1 Ligand-Linker Conjugates 12* E3 ligase Ligand-Linker Conjugates 38	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 12 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 12 can be used to design SNIPERs.

HY-128825

*cIAP1 Ligand-Linker Conjugates 8* E3 ligase Ligand-Linker Conjugates 46	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 8 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 8 can be used to design SNIPERs.

HY-128823

*cIAP1 Ligand-Linker Conjugates 7* E3 ligase Ligand-Linker Conjugates 44	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 7 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 7 can be used to design SNIPERs.

HY-128818

*cIAP1 Ligand-Linker Conjugates 5* E3 ligase Ligand-Linker Conjugates 39	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 5 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 5 can be used to design SNIPERs.

HY-128821

*cIAP1 Ligand-Linker Conjugates 4* E3 ligase Ligand-Linker Conjugates 42	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 4 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 4 can be used to design SNIPERs.

HY-128816

*cIAP1 Ligand-Linker Conjugates 2* E3 ligase Ligand-Linker Conjugates 37	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 2 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 can be used to design SNIPERs.

HY-P1887

*p5 Ligand* for Dnak and DnaJ**	HSP	Infection
p5 Ligand for Dnak and DnaJ is a nonapeptide, which corresponds to the main binding site for the 23-residue part of the presequence of mitochondrial aspartate aminotransferase. p5 Ligand for Dnak and DnaJ is a high-affinity ligand for DnaK and DnaJ.

HY-KT001

*E3 Ligase Ligand-Linker Conjugate Kit*	E3 Ligase Ligand-Linker Conjugate	Cancer
E3 Ligase Ligand-Linker Conjugate Kit is a series of synthesized compounds that incorporate an E3 ligase ligand and a linker used in PROTAC technology.

HY-44148

*FAK ligand-Linker Conjugate 1*	Target Protein Ligand-Linker Conjugate	Cancer
FAK ligand-Linker Conjugate 1 incorporates a ligand for FAK, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). FAK ligand-Linker Conjugate 1 can be extensively used for PROTAC-mediated protein degradation.

HY-129040A

Iobenguane sulfate MIBG sulfate	Others	Cancer
Iobenguane sulfate (MIBG sulfate) is an analogue of the neurotransmitter norepinephrine with antitumor activity. Radioiodinated Iobenguane sulfate is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors. Iobenguane sulfate is a high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation).

HY-42424A

(S,R,S)-AHPC-Me dihydrochloride VHL Ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride	Ligand for E3 Ligase	Cancer
(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-128813A

*cIAP1 Ligand-Linker Conjugates 15 hydrochloride* E3 ligase Ligand-Linker Conjugates 34 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 15 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 hydrochloride can be used to design SNIPERs.

HY-128816A

*cIAP1 Ligand-Linker Conjugates 2 Hydrochloride* E3 ligase Ligand-Linker Conjugates 37 Hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 2 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 Hydrochloride can be used to design SNIPERs.

HY-128812A

*cIAP1 Ligand-Linker Conjugates 11 Hydrochloride* E3 ligase Ligand-Linker Conjugates 33 Hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 11 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 Hydrochloride can be used to design SNIPERs.

HY-128814

*cIAP1 Ligand-Linker Conjugates 6 hydrochloride* E3 ligase Ligand-Linker Conjugates 35 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
cIAP1 Ligand-Linker Conjugates 6 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 6 hydrochloride can be used to design SNIPERs.

HY-12512

cGAMP Cyclic GMP-AMP; 3',3'-cGAMP	STING	Inflammation/Immunology
cGAMP (Cyclic GMP-AMP; 3',3'-cGAMP) is an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA; STING ligand.

HY-42424

(S,R,S)-AHPC-Me hydrochloride VHL Ligand 2 hydrochloride; E3 ligase Ligand 1	Ligand for E3 Ligase	Cancer
(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-130499

*ERRα Ligand-Linker Conjugates 1*	Target Protein Ligand-Linker Conjugate	Cancer
ERRα Ligand-Linker Conjugates 1 incorporates a ligand for estrogen-related receptor alpha (ERRα), and a PROTAC linker, which recruit E3 ligases MDM2. ERRα Ligand-Linker Conjugates 1 can be used in the synthesis of a series of PROTACs, such as PROTAC ERRalpha Degrader-1 (HY-128838). PROTAC ERRalpha Degrader-1 is an ERRα degrader.

HY-10930

UNC0321	Histone Methyltransferase	Cancer
UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 63 pM and with assay-dependent IC₅₀ values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC₅₀ values of 15-23 nM. UNC0321 is inactive against SET7/9, SET8/PreSET7, PRMT3 and JMJD2E.

HY-10929

UNC0224	Histone Methyltransferase	Cancer
UNC0224 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 2.6 nM, an IC₅₀ of 15 nM and a K_d of 23 nM. UNC0224 also potently inhibits b>GLP with assay-dependent IC₅₀ values of 20-58 nM. UNC0224 is inactive against SET7/9, SET8/PreSET7, PRMT3 and JMJD2E.

HY-129608

Lenalidomide-acetylene-C5-COOH Cereblon Ligand-linker Conjugate	E3 Ligase Ligand-Linker Conjugate	Cancer
Lenalidomide-acetylene-C5-COOH (compound 43; Cereblon ligand-linker Conjugate) is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-acetylene-C5-COOH can be connected to the ligand for protein by a linker to form PROTAC.

HY-133189

Bis-propargyl-PEG9	PROTAC Linker	Endocrinology
Bis-propargyl-PEG9 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands.

HY-130295

Pomalidomide-PEG2-Tos Cereblon Ligand-Linker Conjugates 16; E3 ligase Ligand-Linker Conjugates 52	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG2-Tos is an E3 ligase ligand-linker conjugates, composed of a cereblon ligand and two-unit PEG linker.

HY-112078

(S,R,S)-AHPC-Me VHL Ligand 2; E3 ligase Ligand 1A	Ligand for E3 Ligase	Cancer
(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-W007648

Methyl 3-aminopropanoate hydrochloride β-Alanine methyl ester hydrochloride	Others	Others
Methyl 3-aminopropanoate hydrochloride is prepared by esterification of Β-Alanine (I). Methyl 3-aminopropanoate hydrochloride can be used in the synthesis of bidentate pyridine-acid ligand.

HY-107439

Thalidomide-O-amido-C8-NH2 Cereblon Ligand-Linker Conjugates 2; E3 Ligase Ligand-Linker Conjugates 20	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-107438

Thalidomide-O-amido-C4-NH2 Cereblon Ligand-Linker Conjugates 6; E3 Ligase Ligand-Linker Conjugates 19	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-111824

VH032-thiol-C6-NH2 VHL Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 29	E3 Ligase Ligand-Linker Conjugate	Cancer
VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-W087383

Thalidomide 5-fluoride	Ligand for E3 Ligase	Cancer
Thalidomide 5-fluoride is Thalidomide-based cereblon *ligand* that incorporates to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.

HY-N0927

(-)-Isocorypalmine Tetrahydrocolumbamine; (S)-Tetrahydrocolumbamine	Dopamine Receptor	Others
(-)-Isocorypalmine (Tetrahydrocolumbamine), isolated from the crude base fraction of Corydalis chaerophylla, is a dopamine receptor ligand. Recombinant CYP719A21 displays strict substrate specificity and high affinity (K_m=4.63 ± 0.71 μM) for (-)-Isocorypalmine.

HY-130979

EED226-COOH	Ligand for Target Protein for PROTAC	Cancer
EED226-COOH is an EED226-derived ligand for target protein EED ligand for PROTAC, binds to a ligand for VHL via linker to form UNC6852 (HY-130708) to degrade PRC2.

HY-129776

*K-Ras ligand-Linker Conjugate 2*	Target Protein Ligand-Linker Conjugate	Cancer
K-Ras ligand-Linker Conjugate 2 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-129775

*K-Ras ligand-Linker Conjugate 1*	Target Protein Ligand-Linker Conjugate	Cancer
K-Ras ligand-Linker Conjugate 1 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 1 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-103612

Thalidomide-O-amido-C3-COOH Cereblon Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 15	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-133486

GABAA receptor agent 1
GABA Receptor Neurological Disease

GABAA receptor agent 1 is a high affinity ligand for GABAA receptor, with potent anticonvulsant activity.

HY-130822

*K-Ras ligand-Linker Conjugate 4*	Target Protein Ligand-Linker Conjugate	Cancer
K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 4 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130823

*K-Ras ligand-Linker Conjugate 5*	Target Protein Ligand-Linker Conjugate	Cancer
K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 5 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130991

*K-Ras ligand-Linker Conjugate 6*	Target Protein Ligand-Linker Conjugate	Cancer
K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130707

*K-Ras ligand-Linker Conjugate 3*	Target Protein Ligand-Linker Conjugate	Cancer
K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-21930

Pomalidomide-PEG4-C-COOH Cereblon Ligand -Linker Conjugates 1; E3 Ligase Ligand-Linker Conjugates 1	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG4-C-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.

HY-128941

*CCK2R Ligand-Linker Conjugates 1*	Drug-Linker Conjugates for ADC	Cancer
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker.

HY-103614

Thalidomide-O-amido-C8-NH2 (TFA) Cereblon Ligand -Linker Conjugates 2 (TFA); E3 Ligase Ligand-Linker Conjugates 20 (TFA)	E3 Ligase Ligand-Linker Conjugate	Others
Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand -Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-103613

Thalidomide-O-amido-C4-NH2 (TFA) Cereblon Ligand-Linker Conjugates 6 (TFA); E3 ligase Ligand-Linker Conjugates 19 (TFA)	E3 Ligase Ligand-Linker Conjugate	Others
Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-115446A

Lenalidomide-C4-NH2 hydrochloride Cereblon Ligand 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 32 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Lenalidomide-C4-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C4-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC (Compound 24), which has IC₅₀s of 0.98 nM and 13.7 nM in inhibition of RS4;11 and MOLM-13 acute leukemia cell lines growth, respectively.

HY-130716

Thalidomide-NH-C10-COOH	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-NH-C10-COOH (compound 6b) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based von Hippel-Lindau (VHL) ligand and a linker used in PROTAC technology.

HY-130521

Pomalidomide-amido-PEG3-C2-NH2 Cereblon Ligand-Linker Conjugates 22; E3 ligase Ligand-Linker Conjugates 55	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-112618A

Thalidomide-O-amido-C6-NH2 TFA Cereblon Ligand-Linker Conjugates 11 TFA; E3 Ligase Ligand-Linker Conjugates 25 TFA	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-103615

Thalidomide-O-amido-C4-N3 Cereblon Ligand-Linker Conjugates 4; E3 ligase Ligand-Linker Conjugates 18	E3 Ligase Ligand-Linker Conjugate	Others
Thalidomide-O-amido-C4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-107440

Thalidomide-O-amido-PEG3-C2-NH2 Cereblon Ligand-Linker Conjugates 3 ; E3 Ligase Ligand-Linker Conjugates 14	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-122725

Lenalidomide-C5-NH2 Cereblon Ligand-Linker Conjugates 19; E3 ligase Ligand-Linker Conjugates 31	E3 Ligase Ligand-Linker Conjugate	Cancer
Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs.

HY-41549

Pomalidomide-PEG4-Ph-NH2 Cereblon Ligand-Linker Conjugates 9; E3 Ligase Ligand-Linker Conjugates 2	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.

HY-125845

(S,R,S)-AHPC VH032-NH2; VHL Ligand 1	Ligand for E3 Ligase	Cancer
(S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC₅₀ of 1.11 μM in Ba/F3 cells.

HY-N5024

Gambogenic acid	Histone Methyltransferase	Cancer
Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination.

HY-128846

Pomalidomide-C2-NH2 Cereblon Ligand-Linker Conjugates 15	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.

HY-128716

Pomalidomide-PEG3-C2-NH2 Cereblon Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 30	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-112599

Pomalidomide-PEG4-C2-NH2 Cereblon Ligand-Linker Conjugates 8; E3 Ligase Ligand-Linker Conjugates 22	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.

HY-101763A

(S,R,S)-AHPC hydrochloride VH032-NH2 hydrochloride; VHL Ligand 1 hydrochloride	Ligand for E3 Ligase	Cancer
(S,R,S)-AHPC hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC hydrochloride can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC₅₀ of 1.11 μM in Ba/F3 cells.

HY-109176

Giredestrant GDC-9545	Estrogen Receptor/ERR	Cancer
Giredestrant (GDC-9545), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.

HY-115560A

Thalidomide-O-amido-C3-NH2 (TFA) Cereblon Ligand-Linker Conjugates 16 (TFA); E3 Ligase Ligand-Linker Conjugates 52 (TFA)	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-C3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-125884

Pomalidomide-amido-C4-amido-C6-NH-Boc Cereblon Ligand-Linker Conjugates 21; E3 Ligase Ligand-Linker Conjugates 54	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-amido-C4-amido-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-126458

Thalidomide-O-PEG2-propargyl E3 ligase Ligand-Linker Conjugates 32	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-P1868

*α2β1 Integrin Ligand* Peptide**	Integrin	Infection
α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.

HY-136424

GPI-1485
GM1485
Others Neurological Disease

GPI-1485 (GM1485), a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke.

HY-128846A

Pomalidomide-C2-NH2 hydrochloride Cereblon Ligand-Linker Conjugates 15 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-128839

PROTAC ERRα Degrader-2	PROTAC Estrogen Receptor/ERR	Cancer
PROTAC ERRα Degrader-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-2 is an estrogen-related receptor alpha (ERRa) degrader.

HY-12759

CARM1-IN-1	Histone Methyltransferase	Cancer
CARM1-IN-1 is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).

HY-12759A

CARM1-IN-1 hydrochloride	Histone Methyltransferase	Cancer
CARM1-IN-1 hydrochloride is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).

HY-101938

Sinefungin Adenosyl-Ornithine; A-9145; Antibiotic 32232RP	Histone Methyltransferase Fungal Antibiotic	Infection Inflammation/Immunology
Sinefungin is a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication. Sinefungin, a *SET7/9* inhibitor, ameliorates renal fibrosis by inhibiting H3K4 methylation.

HY-128716A

Pomalidomide-PEG3-C2-NH2 (TFA) Cereblon Ligand-Linker Conjugates 5 (TFA) ; E3 ligase Ligand-Linker Conjugates 30 (TFA)	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-110402

(S,R,S)-AHPC TFA VH032-NH2 TFA; VHL Ligand 1 TFA	Ligand for E3 Ligase	Cancer
(S,R,S)-AHPC TFA (VH032-NH2 TFA) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC TFA can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC₅₀ of 1.11 μM in Ba/F3 cells.

HY-P1868A

*α2β1 Integrin Ligand* Peptide TFA**	Integrin	Others
α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.

HY-125846

(S,R,S)-AHPC-PEG1-OTs VH032-PEG1-OTs; VHL Ligand-Linker Conjugates 2; E3 ligase Ligand-Linker Conjugates 51	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG1-OTs is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.

HY-135903

Giredestrant tartrate GDC-9545 tartrate	Estrogen Receptor/ERR	Cancer
Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity.

HY-13713

LY377604	Adrenergic Receptor	Metabolic Disease Endocrinology
LY377604 is a *human β₃-adrenergic* receptor agonist with an EC₅₀ of 2.4 nM and also a β₁- and β₂-adrenergic receptor** antagonist.

HY-112617A

Thalidomide-O-amido-PEG2-C2-NH2 TFA Cereblon Ligand-Linker Conjugates 10 TFA; E3 Ligase Ligand-Linker Conjugates 24 TFA	E3 Ligase Ligand-Linker Conjugate	Cancer Inflammation/Immunology
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-103611

Thalidomide-O-amido-PEG3-C2-NH2 (TFA) Cereblon Ligand-Linker Conjugates 3 (TFA); E3 ligase Ligand-Linker Conjugates 14 (TFA)	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-125883

Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc Cereblon Ligand-Linker Conjugates 20; E3 Ligase Ligand-Linker Conjugates 53	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-122136

S26131	Melatonin Receptor	Neurological Disease
S26131 (compound 5) is a potent and selective MT1 melatoninergic ligand, and the K_i values are 0.5 and 112 nM for MT1 and MT2, respectively. S26131 behaves as an MT1 and MT2 antagonist.

HY-B0163

Detomidine	Adrenergic Receptor	Neurological Disease Endocrinology
Detomidine produce dose-dependent sedative and analgesic effects, is a nonnarcotic, synthetic α2-adrenergic agonist Target: α2-adrenergic agonist Detomidine is an imidazole derivative and α2-adrenergic agonist, used as a large animal sedative, primarily used in horses.

HY-B0163A

Detomidine hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Detomidine hydrochloride produce dose-dependent sedative and analgesic effects, is a nonnarcotic, synthetic α2-adrenergic agonist Target: α2-adrenergic agonist Detomidine is an imidazole derivative and α2-adrenergic agonist, used as a large animal sedative, primarily used in horses.

HY-128832

Nutlin-C1-amido-PEG4-C2-N3 MDM2 Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 48	E3 Ligase Ligand-Linker Conjugate	Cancer
Nutlin-C1-amido-PEG4-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Nutlin 3 based MDM2 ligand and 4-unit PEG linker used in PROTAC technology.

HY-103599

(S,R,S)-AHPC-PEG2-N3 VH032-PEG2-N3; VHL Ligand-Linker Conjugates 6; E3 ligase Ligand-Linker Conjugates 13	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology.

HY-103601

(S,R,S)-AHPC-PEG4-N3 VH032-PEG4-N3; VHL Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 4	E3 Ligase Ligand-Linker Conjugate	Others
(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.

HY-103600

(S,R,S)-AHPC-PEG1-N3 VH032-PEG1-N3; VHL Ligand-Linker Conjugates 9; E3 ligase Ligand-Linker Conjugates 3	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.

HY-103598

(S,R,S)-AHPC-PEG3-N3 VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 12	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG3-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

HY-B0225

L-(-)-α-Methyldopa MK-351; Methyldopa	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Methyldopa is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a sympatholytic or antihypertensive.

HY-114176

(S,R,S)-AHPC-C4-NH2 hydrochloride VH032-C4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 28	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.

HY-B0225B

L-(-)-α-Methyldopa (hydrate) MK-351 hydrate; Methyldopa hydrate	Adrenergic Receptor	Cardiovascular Disease Endocrinology
L-(-)-α-Methyldopa hydrate is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a sympatholytic or antihypertensive.

HY-B0225A

L-(-)-α-Methyldopa hydrochloride MK-351 hydrochloride; Methyldopa hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
L-(-)-α-Methyldopa hydrochloride is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a sympatholytic or antihypertensive.

HY-103602A

(S,R,S)-AHPC-PEG3-NH2 VH032-PEG3-NH2; VHL Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 5 Free Base	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

HY-103604A

(S,R,S)-AHPC-PEG4-NH2 VH032-PEG4-NH2; VHL Ligand-Linker Conjugates 4 ; E3 ligase Ligand-Linker Conjugates 7 Free Base	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.

HY-128848

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH Cereblon Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 49	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130271

(S,R,S)-AHPC-PEG5-COOH VH032-PEG5-COOH; VHL Ligand-Linker Conjugates 16; E3 Ligase Ligand-Linker Conjugates 58	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 5-unit PEG linker used in PROTAC technology.

HY-103604

(S,R,S)-AHPC-PEG4-NH2 hydrochloride VH032-PEG4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 4 hydrochloride; E3 ligase Ligand-Linker Conjugates 7	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.

HY-103602

(S,R,S)-AHPC-PEG3-NH2 hydrochloride VH032-PEG3-NH2 hydrochloride; VHL Ligand-Linker Conjugates 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 5	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

HY-P1483

Urotensin II, mouse	Urotensin Receptor	Neurological Disease Cardiovascular Disease
Urotensin II, mouse is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse is a potent vasoconstrictor. Urotensin II, mouse plays a physiological role in the central nervous system.

HY-P1483B

Urotensin II, mouse acetate	Urotensin Receptor	Neurological Disease Cardiovascular Disease
Urotensin II, mouse acetate is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse acetate is a potent vasoconstrictor. Urotensin II, mouse acetate plays a physiological role in the central nervous system.

HY-100699

Clenproperol
Adrenergic Receptor Endocrinology

Clenproperol is a β2-adrenergic agonist.
HY-17503B

Metoprolol Tartrate
Adrenergic Receptor Cardiovascular Disease Endocrinology

Metoprolol is a cardioselective β1-adrenergic blocking agent.

HY-130982

Lenalidomide-PEG3-iodine	E3 Ligase Ligand-Linker Conjugate	Cancer
Lenalidomide-PEG3-iodine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a 3-unit PEG linker. Lenalidomide-PEG3-iodine can be used in the synthesis of a series of PROTACs, such as SJF620 (HY-133137). SJF620 is a potent PROTAC BTK degrader with a DC₅₀ of 7.9 nM.

HY-130798

(S,R,S)-AHPC-amido-C5-acid	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-amido-C5-acid incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used to design XY028-133 (HY-129180).

HY-B0436

Salbutamol hemisulfate Albuterol hemisulfate; AH-3365 hemisulfate	Adrenergic Receptor Autophagy	Inflammation/Immunology Endocrinology Cancer
Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting β2 adrenergic receptor agonist Target: β2 Adrenergic Receptor Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD.

HY-112600A

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 Cereblon Ligand-Linker Conjugates 12 TFA; E3 Ligase Ligand-Linker Conjugates 23 TFA	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-130813

BET-IN-6	Ligand for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BET-IN-6 is a potent and high affnity BRD2/BRD4 inhibitor. BET-IN-6 is the *ligand* for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612).

HY-P1483A

Urotensin II, mouse TFA	Urotensin Receptor	Neurological Disease Cardiovascular Disease
Urotensin II, mouse TFA is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse TFA is a potent vasoconstrictor. Urotensin II, mouse TFA plays a physiological role in the central nervous system.

HY-123109

(S,R,S)-AHPC-Boc VH032-Boc	Ligand for E3 Ligase	Cancer
(S,R,S)-AHPC-Boc (VH032-Boc) is a ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Boc is used in PROTAC technology.

HY-131005

Ehp inhibitor 2
Ephrin Receptor Cancer

Ehp inhibitor 2 is a Eph family tyrosine kinase inhibitor.

HY-125843

Pomalidomide-PEG1-C2-N3 Cereblon Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 50	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10. CP-10 induces the degradation of CDK6 with an DC₅₀ of 2.1 nM.

HY-12721

Clonidine
Adrenergic Receptor Neurological Disease

Clonidine is an alpha 2-adrenergic agonist which is used extensively in anesthesia research.

HY-B0391

Naftopidil KT-611; BM-15275	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil (Flivas), a selective α1-adrenergic receptor antagonist or alpha blocker, is an antihypertensive drug.

HY-103603A

(S,R,S)-AHPC-PEG2-NH2 VH032-PEG2-NH2 ; VHL Ligand-Linker Conjugates 3 ; E3 ligase Ligand-Linker Conjugates 6 Free Base	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.

HY-17457

Levalbuterol tartrate Levosalbutamol tartrate	Adrenergic Receptor	Neurological Disease Endocrinology
Levosalbutamol tartrate(levalbuterol) is the R-enantiomer of the short-acting β2-adrenergic receptor agonist salbutamol.

HY-B0194A

Tizanidine hydrochloride	Adrenergic Receptor	Cancer Neurological Disease Endocrinology
Tizanidine hydrochloride is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.

HY-B0098

Doxazosin UK 33274	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-B0194

Tizanidine	Adrenergic Receptor	Neurological Disease Endocrinology Cancer
Tizanidine is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.

HY-B0098A

Doxazosin mesylate UK 33274 mesylate	Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-12715

Yohimbine
Adrenergic Receptor Neurological Disease Endocrinology

Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC50 of 0.6 μM.

HY-103603

(S,R,S)-AHPC-PEG2-NH2 hydrochloride VH032-PEG2-NH2 hydrochloride; VHL Ligand-Linker Conjugates 3 hydrochloride; E3 ligase Ligand-Linker Conjugates 6	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.

HY-B0447A

L-Epinephrine Bitartrate (-)-Epinephrine (+)-bitartrate salt; L-Adrenaline (+)-bitartrate salt	Adrenergic Receptor	Neurological Disease Endocrinology
L-Epinephrine bitartrate is an *α-adrenergic* and *β-adrenergic* receptor agonist. L-Epinephrine is a hormone secreted by the medulla of the adrenal glands.

HY-U00402

Fenmetozole Tosylate	Adrenergic Receptor	Neurological Disease Endocrinology
Fenmetozole Tosylate is an antagonist of the actions of ethanol, also antagonizes α2-adrenergic receptor, and acts as an antidepressant drug.

HY-128352

SMYD3-IN-1
Histone Methyltransferase Cancer

SMYD3-IN-1 (compound 29) is an irreversible and selective inhibitor of SMYD3 (SET and MYND domain containing 3), with an IC₅₀ of 11.7 nM.

HY-B0459

Scopine 6,7-Epoxytropine	Adrenergic Receptor	Neurological Disease Endocrinology
Scopine is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.

HY-14302

Salmeterol
GR33343X
Adrenergic Receptor Endocrinology

Salmeterol is a long-acting beta2-adrenergic receptor (beta 2AR) agonist used clinically to treat asthma.
HY-B0659

Brimonidine
UK 14304; AGN190342
Adrenergic Receptor Endocrinology

Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.

HY-B0802

Terbutaline sulfate Terbutaline hemisulfate	Adrenergic Receptor Bacterial Antibiotic	Infection Endocrinology Inflammation/Immunology
Terbutaline sulfate is a β2-adrenergic receptor agonist; a fast-acting bronchodilator and a tocolytic to delay premature labor.

HY-103214

Bucindolol	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Bucindolol is a β1-adrenergic receptor blocker, with intrinsic sympathomimetic activity, used in the research of heart failure.

HY-100699S

Clenproperol-D7
Adrenergic Receptor Endocrinology

Clenproperol-D7 is the deuterium labeled Clenproperol. Clenproperol is a β2-adrenergic agonist.

HY-U00371

AR-08	Adrenergic Receptor	Neurological Disease Endocrinology
AR-08 is an agonist of α2-adrenergic receptor, used for the treatment of attention deficit hyperactivety disorder (ADHD).

HY-B0447

DL-Epinephrine (±)-Epinephrine; DL-Adrenaline; (±)-Adrenaline	Adrenergic Receptor	Neurological Disease Endocrinology
DL-Epinephrine is the racemate of epinephrine. L-Epinephrine is a hormone secreted by the medulla of the adrenal glands. L-Epinephrine is an *α-adrenergic* and *β-adrenergic* receptor agonist.

HY-B1392

Esmolol hydrochloride
Adrenergic Receptor Autophagy Mitophagy Cardiovascular Disease Endocrinology

Esmolol hydrochloride is a beta adrenergic receptor blocker.
HY-101658

Pargolol hydrochloride
Ko 1400 hydrochloride
Adrenergic Receptor Neurological Disease Endocrinology

Pargolol hydrochloride is a β adrenergic receptor antagonist.
HY-101817

Spirendolol
Li 32-468; S 32-468; Substance 32468
Adrenergic Receptor Neurological Disease Endocrinology

Spirendolol is a β adrenergic receptor antagonist.
HY-B0659A

Brimonidine tartrate
UK 14304 tartrate; AGN190342 tartrate
Adrenergic Receptor Endocrinology

Brimonidine tartrate (UK 14304 tartrate) is a full α2-adrenergic receptor (α2-AR) agonist.
HY-13338S

Mabuterol-D9
Adrenergic Receptor Inflammation/Immunology Cardiovascular Disease

Mabuterol-D9 is a deuterium labeled Mabuterol. Mabuterol is an agonist of the β2-adrenergic receptor.
HY-101815

Lidanserin
ZK-33839
5-HT Receptor Adrenergic Receptor Neurological Disease Endocrinology

Lidanserin (ZK-33839) acts as a 5-HT_2A and α₁-adrenergic receptor antagonist.

HY-B1347

Clorprenaline hydrochloride	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Clorprenaline hydrochloride is a β₂-adrenergic receptor agonist that is implicated in bronchial expansion. Clorprenaline has the potential for asthma research.

HY-U00313

Tropodifene
Tropaphen
Adrenergic Receptor Cardiovascular Disease Endocrinology

Tropodifene (Tropaphen) is an α-Adrenergic receptor inhibitor.
HY-101717

Indanidine
Adrenergic Receptor Cardiovascular Disease Endocrinology

Indanidine is an alpha-adrenergic agonist.
HY-U00016

Teoprolol
Adrenergic Receptor Endocrinology

Teoprolol is a β-adrenergic receptor blocker.

HY-101178

L-689560	iGluR	Neurological Disease
L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases.

HY-136363

MDR-652	TRP Channel	Neurological Disease
MDR-652 is a highly specific and efficacious transient receptor potential vanilloid 1 (TRPV1) ligand with agonist activity. The K_is are 11.4 and 23.8 nM for hTRPV1 and rTRPV1, respectively. The EC₅₀s are 5.05 and 93 nM for hTRPV1 and rTRPV1, respectively. Potent topical analgesic activity.

HY-B0459A

Scopine hydrochloride 6,7-Epoxytropine hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Scopine hydrochloride (6,7-Epoxytropine hydrochloride) is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.

HY-B1037

Salbutamol Albuterol; AH-3365	Adrenergic Receptor	Neurological Disease Endocrinology
Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).

HY-121879

SHP836
Phosphatase Cancer

SHP836 is a SHP2 allosteric inhibitor, with an IC₅₀ of 12 μM for the full length SHP2.

HY-B1154

Penbutolol sulfate (-)-Terbuclomine	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Penbutolol sulfate is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker.

HY-B1270

Isoxsuprine hydrochloride	Adrenergic Receptor iGluR	Neurological Disease Endocrinology
Isoxsuprine hydrochloride is a *beta-adrenergic* receptor agonist with K_i*s of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic* receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor antagonist.

HY-101385

L-765314	Adrenergic Receptor	Cardiovascular Disease Endocrinology
L-765314 is a potent and selective *α1b adrenergic* receptor antagonist with K_i*s of 5.4 nM and 2.0 nM for rat and human α1b adrenergic* receptor, respectively.

HY-U00205

Dopexamine hydrochloride
FPL60278AR
Adrenergic Receptor Cardiovascular Disease Endocrinology

Dopexamine hydrochloride is a β2 adrenergic receptor agonist.
HY-U00110

MG 1
Adrenergic Receptor Cardiovascular Disease Endocrinology

MG 1 is an α1 adrenergic receptor antagonist.
HY-U00123

Guanoxabenz
Hydroxyguanabenz
Adrenergic Receptor Cardiovascular Disease Endocrinology

Guanoxabenz is an α2 adrenergic receptor agonist.
HY-101691

Ecastolol
Adrenergic Receptor Cardiovascular Disease Endocrinology

Ecastolol is a beta adrenergic receptor antagonist, with antianginal activities.
HY-100141

Ancarolol
Adrenergic Receptor Cardiovascular Disease Endocrinology

Ancarolol is a beta-adrenergic blocking agent.

HY-N0132A

Synephrine hydrochloride Oxedrine hydrochloride	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Synephrine hydrochloride (Oxedrine hydrochloride) is an *α-adrenergic* and *β-adrenergic* agonist derived from the Citrus aurantium, it has sympathomimetic and structural similarities to ephedra and ephedrine alkaloids.

HY-N0132

Synephrine Oxedrine	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Synephrine (Oxedrine) is an *α-adrenergic* and *β-adrenergic* agonist derived from the Citrus aurantium, it has sympathomimetic and structural similarities to ephedra and ephedrine alkaloids.

HY-135236

OXFBD04	Epigenetic Reader Domain	Cancer
OXFBD04 is a potent and selective BRD4 inhibitor with an IC₅₀ of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity.

HY-131295

PD0325901-O-C2-dioxolane	MEK Ligand for Target Protein for PROTAC	Cancer
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.

HY-U00391

β3-AR agonist 2
Adrenergic Receptor Metabolic Disease Endocrinology

β₃-AR agonist 2 is a potent and selective β₃-adrenergic receptor (β₃-AR) agonist with an EC₅₀ of 8 nM.

HY-101325

BRL 37344 sodium BRL 37344A	Adrenergic Receptor	Metabolic Disease Endocrinology
BRL 37344 sodium (BRL 37344A) is a specific β3-adrenergic receptor agonist. BRL 37344 sodium treatment significantly lowers the body weight of obese mice.

HY-B0532A

Trifluoperazine dihydrochloride TFP; SKF5019	Dopamine Receptor Autophagy Influenza Virus Adrenergic Receptor	Neurological Disease Cancer
Trifluoperazine dihydrochloride (TFP) is an antipsychotic phenothiazine agent and a selective α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is also a potent dopamine D2 receptor inhibitor.

HY-100255

Tiodazosin
BL-5111
Adrenergic Receptor Neurological Disease Endocrinology

Tiodazosin is a potent competitive postsynaptic alpha adrenergic receptor antagonist.
HY-16316

Metipranolol hydrochloride
Adrenergic Receptor Cardiovascular Disease Endocrinology

Metipranolol hydrochloride is a non-selective β adrenergic receptor blocking agent.

HY-U00367

(4E)-SUN9221	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease Endocrinology
(4E)-SUN9221 is a potent antagonist of α1-adrenergic receptor and 5-HT2 receptor, with antihypertensive and anti-platelet aggregation activities.

HY-131106S

Clorprenaline D7	Adrenergic Receptor	Endocrinology Inflammation/Immunology
Clorprenaline D7 is a deuterium labeled Clorprenaline. Clorprenaline is a β2-adrenergic receptor agonist that is implicated in bronchial expansion. Clorprenaline has the potential for asthma research.

HY-A0027

Fenspiride Hydrochloride
Adrenergic Receptor Histamine Receptor Inflammation/Immunology Endocrinology

Fenspiride Hcl is an α adrenergic and H1 histamine receptor antagonist.
HY-U00293

ZK-90055 hydrochloride
Adrenergic Receptor Inflammation/Immunology Endocrinology

ZK-90055 hydrochloride is a β2 adrenergic receptor agonist.

HY-131145

Brombuterol hydrochloride Bromobuterol hydrochloride	Adrenergic Receptor	Inflammation/Immunology
Brombuterol hydrochloride (Bromobuterol hydrochloride) is a *β-adrenergic* receptor** agonist.

HY-101585

Imoxiterol
RP 58802B
Adrenergic Receptor Neurological Disease Endocrinology

Imoxiterol (RP 58802B) is a β-adrenergic agonist.

HY-B0532S

Trifluoperazine D8	Adrenergic Receptor Dopamine Receptor Influenza Virus Autophagy	Cancer Neurological Disease
Trifluoperazine D8 is a deuterium labeled Trifluoperazine. Trifluoperazine is an antipsychotic phenothiazine agent and a selective α1-adrenergic receptor antagonist. Trifluoperazine is also a potent dopamine D2 receptor inhibitor .

HY-B1276A

Metaproterenol Orciprenaline	Adrenergic Receptor	Inflammation/Immunology Cardiovascular Disease Endocrinology
Metaproterenol (Orciprenaline) is a direct-acting sympathomimetic and a β2-adrenergic receptor (β2AR) agonist with an IC₅₀ of 68 nM. Metaproterenol also has anti-inflammatory activity.

HY-121186

Bevantolol hydrochloride	Adrenergic Receptor Calcium Channel	Metabolic Disease Neurological Disease
Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca²⁺ antagonist.

HY-P1318

Ac-RYYRIK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain.

HY-P1318A

Ac-RYYRIK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain.

HY-B0452

Ritodrine hydrochloride
DU21220 hydrochloride
Adrenergic Receptor Endocrinology

Ritodrine hydrochloride (DU21220 hydrochloride) is a β-2 adrenergic receptor agonist.

HY-B0381B

Levobetaxolol hydrochloride (S)-Betaxolol hydrochloride; AL-1577A	Adrenergic Receptor	Neurological Disease Endocrinology
Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye.

HY-12710A

Rauwolscine hydrochloride α-Yohimbine hydrochloride; Corynanthidine hydrochloride; Isoyohimbine hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Rauwolscine hydrochloride is a potent and specific α2 adrenergic receptor antagonist with a K_i of 12 nM.

HY-B0076

(±)-Bisoprolol hemifumarate Bisoprolol hemifumarate salt	Adrenergic Receptor	Inflammation/Immunology Endocrinology
(±)-Bisoprolol (hemifumarate) is a selective type β1 adrenergic receptor blocker.

HY-A0066

Tolazoline
Imidaline; NSC35110
Adrenergic Receptor Endocrinology

Tolazoline(Imidaline) is a non-selective competitive α-adrenergic receptor antagonist.

HY-B0203A

Nebivolol hydrochloride R 065824 hydrochloride	Adrenergic Receptor Apoptosis	Cardiovascular Disease Endocrinology
Nebivolol hydrochloride selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM.

HY-B0203

Nebivolol
R 065824
Adrenergic Receptor Cardiovascular Disease Endocrinology

Nebivolol selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM.

HY-135119

Salmeterol-D3	Adrenergic Receptor
Salmeterol-D3 is the deuterium labeled Salmeterol (HY-14302). Salmeterol is a long-acting beta2-adrenergic receptor agonist that is used for the study of asthma and chronic obstructive pulmonary disease (COPD).

HY-101610

OPC-28326	Adrenergic Receptor	Cardiovascular Disease Endocrinology
OPC-28326 is a selective peripheral vasodilator and an angatonist of α2-adrenergic receptor, with K_i of 2040, 285, and 55 nM for α2A-, α2B- and α2C-adrenoceptors, respectively.

HY-B0035

Sulfamethazine Sulfadimidine; Sulfadimerazine	Bacterial Antibiotic	Infection
Sulfamethazine (Sulfadimidine) is an antimicrobial that is widely used to treat and prevent various animal diseases (such as gastrointestinal and respiratory tract infections). In China and the European Commission, the maximum residue level for Sulfamethazine in animal product is set at 100 µg/kg.

HY-B0035A

Sulfamethazine sodium Sulfadimidine sodium; Sulfadimerazine sodium	Bacterial Antibiotic	Infection
Sulfamethazine sodium (Sulfadimidine sodium) is an antimicrobial that is widely used to treat and prevent various animal diseases (such as gastrointestinal and respiratory tract infections). In China and the European Commission, the maximum residue level for Sulfamethazine sodium in animal product is set at 100 µg/kg.

HY-19373

RWJ-445167 3DP-10017	Thrombin Factor Xa	Cardiovascular Disease
RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with K_i of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.

HY-16787

ICA-121431	Sodium Channel	Cardiovascular Disease
ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Na_v) blocker, shows equipotent selectivity for human Na_v1.1 and Na_v1.3 subtypes with IC₅₀ values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Na_v1.2 (IC₅₀=240 nM) and 1,000 fold selectivity against Na_v1.4, Na_v1.6, and the TTX-resistant human Na_v1.5 and Na_v1.8 channels (IC₅₀s >10 µM).

HY-B1276

Metaproterenol hemisulfate Orciprenaline hemisulfate	Adrenergic Receptor	Inflammation/Immunology Cardiovascular Disease Endocrinology
Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a β2-adrenergic receptor (β2AR) agonist with an IC₅₀ of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity.

HY-135895

Detomidine carboxylic acid	Adrenergic Receptor	Endocrinology Neurological Disease
Detomidine carboxylic acid is the major urinary metabolite of Detomidine. Detomidine is a synthetic *α2-adrenergic* agonist and an animal analgesic sedative. Detomidine also has cardiac and respiratory effects and an antidiuretic action.

HY-B1675

Levalbuterol (R)-Albuterol; (R)-Salbutamol; Levosalbutamol	Adrenergic Receptor	Inflammation/Immunology
Levalbuterol ((R)-Albuterol; (R)-Salbutamol) is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD.

HY-U00386

Bometolol Hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Bometolol Hydrochloride is a *beta-adrenergic* blocking agent, used for the research of cardiovascular disease.

HY-101094

Ocaperidone R79598	5-HT Receptor Dopamine Receptor	Neurological Disease
Ocaperidone is an effective antipsychotic agent, acting as a potent 5-HT₂ and dopamine D₂ antagonist, and a 5-HT_1A agonist, with K_is of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT₂, a₁-adrenergic receptor, dopamine D₂, histamine H₁ and a₂-adrenergic receptor, respectively, and a pEC₅₀ and pK_i of 7.60 and 8.08 for h5-HT_1A.

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes.

HY-B0443A

Xylazine hydrochloride BAY 1470 hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Xylazine hydrochloride (BAY 1470 hydrochloride) is a strong *α2-adrenergic* agonist whose effects are mediated via stimulation of central α2-receptors. Xylazine hydrochloride is used as a sedative, analgesic and muscle relaxant in veterinary medicine.

HY-B0443

Xylazine BAY 1470	Adrenergic Receptor	Neurological Disease Endocrinology
Xylazine (BAY 1470) is a strong *α2-adrenergic* agonist whose effects are mediated via stimulation of central α2-receptors. Xylazine hydrochloride is used as a sedative, analgesic and muscle relaxant in veterinary medicine.

HY-A0066A

Tolazoline hydrochloride Imidaline hydrochloride; NSC35110 hydrochloride	Adrenergic Receptor	Endocrinology
Tolazoline (hydrochloride)(Imidaline (hydrochloride)) Hcl is a non-selective competitive α-adrenergic receptor antagonist.

HY-B1108

Labetalol hydrochloride AH-5158 hydrochloride; Sch-15719W	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Labetalol hydrochloride is a mixed alpha/beta adrenergic antagonist that is used to treat high blood pressure.

HY-U00283

Falintolol, (Z)-
Adrenergic Receptor Endocrinology

Falintolol, (Z)-, a new β-adrenergic antagonist, is characterized by the presence of an oxime function.
HY-U00404

Phentolamine Analogue 1
Others Metabolic Disease Endocrinology

Phentolamine Analogue 1 is an analogue of phentolamine. Phentolamine is a nonselective alpha-adrenergic antagonist.

HY-103076

EZ-482	Others	Neurological Disease
EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with K_ds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas.

HY-B0381A

Betaxolol hydrochloride SL75212	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Betaxolol Hydrochloride is a selective *beta1 adrenergic* receptor** blocker that can be used for the research of hypertension and glaucoma.

HY-B0192A

Alfuzosin hydrochloride
SL 77499-10
Adrenergic Receptor Endocrinology

Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).
HY-B0192

Alfuzosin
SL 77499
Adrenergic Receptor Endocrinology

Alfuzosin is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0381

Betaxolol	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Betaxolol is a selective *beta1 adrenergic* receptor** blocker that can be used for the research of hypertension and glaucoma.

HY-U00439A

*Protein kinase inhibitors* 1 hydrochloride** (E)-5-((2-Oxo-6'-(piperazin-1-yl)-1,2-dihydro-[3,3'-bipyridin]-5-yl)methylene)thiazolidine-2,4-dione hydrochloride	DYRK	Cancer
Protein kinase inhibitors 1 hydrochloride is a potent HIPK2 inhibitor, with IC₅₀s of 136 and 74 nM for HIPK1 and HIPK2, and a K_d of 9.5 nM for HIPK2.

HY-B0781

Promethazine hydrochloride	Histamine Receptor	Neurological Disease Endocrinology
Promethazine hydrochloride is the first-generation antihistamine; strong antagonist of the H1 receptor and moderate mACh receptor antagonist, moderate affinity for 5-HT2A, 5-HT2C, D2 and α1-adrenergic receptors.

HY-103608

(S,R,S)-AHPC-(C3-PEG)2-C6-Cl VHL Ligand-Linker Conjugates 11; E3 ligase Ligand-Linker Conjugates 11	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-(C3-PEG)2-C6-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-PEG)2-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-114091

PF-00356231 hydrochloride	MMP	Inflammation/Immunology
PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC₅₀=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC₅₀s of 0.00065, 1.7, 0.98, 0.39 μM, respectively.

HY-19057A

Vatinoxan hydrochloride MK-467 hydrochloride; L-659066 hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Vatinoxan hydrochloride (MK-467 hydrochloride;L-659066 hydrochloride) is a peripheral *α2 adrenergic* receptor** antagonist.

HY-W012037

8-Hydroxyquinoline hemisulfate 8-Quinolinol hemisulfate	Bacterial Antibiotic	Infection
8-Hydroxyquinoline hemisulfate (8-Quinolinol hemisulfate) is a monoprotic bidentate chelating agent, exhibits antiseptic, disinfectant, and pesticide properties, functioning as a transcription inhibitor.

HY-B0566

Guanabenz Acetate BR-750; Wy8678 acetate	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Guanabenz (Acetate) (BR-750) is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.

HY-131105S

Cimbuterol-D9
Adrenergic Receptor Cardiovascular Disease

Cimbuterol-D9 is the deuterium labeled Cimbuterol. Cimbuterol is aβ-adrenergic agonist.
HY-A0142A

Dapiprazole hydrochloride
Adrenergic Receptor Endocrinology

Dapiprazole hydrochloride is a potent α-adrenergic blocking drug, which is used to reverse mydriasis after eye examination.

HY-131103

Phenylethanolamine A	Adrenergic Receptor	Metabolic Disease Inflammation/Immunology
Phenylethanolamine A acts as a *β-adrenergic* agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.

HY-B0468

Isoprenaline hydrochloride Isoproterenol hydrochloride	Adrenergic Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Isoprenaline hydrochloride is a non-selective *beta-adrenergic* receptor** agonist with potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities.

HY-10791

Ritanserin R 55667	5-HT Receptor Histamine Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
Ritanserin (R 55667) is a highly potent, relatively selective, orally active, long acting antagonist of 5-HT₂ receptor, with an IC₅₀ of 0.9 nM, less active on Histamine H₁, Dopamine D₂, Adrenergic α₁, Adrenergic α₂ receptors.

HY-103606

(S,R,S)-AHPC-PEG6-C4-Cl VH032-PEG6-C4-Cl; VHL Ligand-Linker Conjugates 10; E3 ligase Ligand-Linker Conjugates 9	PROTAC	Cancer
(S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-103607

(S,R,S)-AHPC-PEG2-C4-Cl VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10	PROTAC	Cancer
(S,R,S)-AHPC-PEG2-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-PEG2-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-12962

NMDA-IN-1	iGluR	Neurological Disease
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.

HY-17034B

Medetomidine hydrochloride MPV785	Adrenergic Receptor	Neurological Disease Endocrinology
Medetomidine hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic and sedative properties.

HY-B1238

Pronethalol (±)-Pronethalo	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Pronethalol is a non-selective beta-adrenergic blocking agent, protect against and to reverse Digitalis-induced ventricular arrhythmias.

HY-17034A

Dexmedetomidine hydrochloride (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride	Adrenergic Receptor Autophagy	Neurological Disease Endocrinology Cancer
Dexmedetomidine Hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic and sedative properties.

HY-113962

7α,25-Dihydroxycholesterol 7α,25-OHC	EBI2/GPR183 Endogenous Metabolite	Inflammation/Immunology
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC₅₀=140 pM; K_d=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells.

HY-124699

MMSET-IN-1	Others	Cancer
MMSET-IN-1 is a multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) inhibitor against SETD2 and MMSET with IC₅₀s of 0.49 and 3.3 μM, respectively. MMSET-IN-1 has a K_d of 1.6 μM for MMSET.

HY-131104S

Brombuterol D9 Bromobuterol D9	Adrenergic Receptor	Inflammation/Immunology
Brombuterol D9 (Bromobuterol D9) is a deuterium labeled Brombuterol. Brombuterol is a *β-adrenergic* receptor** agonist.

HY-15726

ICI 89406
Adrenergic Receptor Metabolic Disease

ICI 89406 is a selective β1 adrenergic receptor antagonist amenable to labelling with positron emitters, for PET.

HY-13715

Norepinephrine Levarterenol; L-Noradrenaline	Endogenous Metabolite Adrenergic Receptor Autophagy	Endocrinology Cardiovascular Disease
Norepinephrine (Levarterenol; L-Noradrenaline) is a β₁-selective adrenergic receptor agonist with EC₅₀ of 5.37 μM.

HY-B0193

Prazosin	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder.

HY-B0528A

Octopamine hydrochloride (±)-p-Octopamine hydrochlorid	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Octopamine hydrochloride ((±)-p-Octopamine hydrochlorid) is an endogenous biogenic amine that is closely related to norepinephrine, and has effects on the adrenergic and dopaminergic systems.

HY-B0193A

Prazosin hydrochloride	Adrenergic Receptor Autophagy	Cardiovascular Disease Endocrinology Cancer
Prazosin hydrochloride is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder.

HY-13715A

Norepinephrine hydrochloride Levarterenol hydrochloride; L-Noradrenaline hydrochloride	Adrenergic Receptor Autophagy	Cardiovascular Disease Endocrinology
Norepinephrine hydrochloride (Levarterenol hydrochloride) is a β₁-selective adrenergic receptor agonist with EC₅₀ of 5.37 μM.

HY-131104AS

Brombuterol D9 hydrochloride Bromobuterol D9 hydrochloride	Adrenergic Receptor	Inflammation/Immunology
Brombuterol D9 hydrochloride (Bromobuterol D9 hydrochloride) is a deuterium labeled Brombuterol hydrochloride. Brombuterol hydrochloride is a *β-adrenergic* receptor** agonist.

HY-19436

Solabegron GW 427353	Adrenergic Receptor	Metabolic Disease Endocrinology
Solabegron (GW 427353) is a selective β₃-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β₃-AR, with an EC₅₀ value of 22 nM. Solabegron (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome.

HY-B0976

Fenoterol Th-1165; Phenoterol	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Fenoterol is a β 2 adrenergic agonist designed to open up the airways to the lungs, is classed as sympathomimetic β2 agonist and asthma medication.

HY-B2111

(R)-(+)-Atenolol
Adrenergic Receptor Others

(R)-(+)-Atenolol is the less active enantiomer of the (R,S)-atenolol. (R,S)-atenolol is a β-adrenergic receptor antagonist.
HY-113356

m-Tyramine
Endogenous Metabolite Neurological Disease

m-Tyramine is an endogenous trace amine neuromodulator. m-Tyramine has effects on the adrenergic and dopaminergic receptor^{[1, 2]}.

HY-135813

LtaS-IN-1	Bacterial	Infection
LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely.

HY-125957

A-3 hydrochloride	PKA Casein Kinase CaMK PKC	Others
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (K_i=4.3 µM), casein kinase II (K_i=5.1 µM) and myosin light chain kinase (MLCK) (K_i=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with K_i values of 47 µM and 80 µM, respectively.

HY-113534

MV1
IAP Others

MV1 is an antagonist of IAP (inhibitor of apoptosis protein), leads to protein knockdown of HaloTag-fused proteins when combined with HaloTag ligand.

HY-A0003B

Lenalidomide hemihydrate CC-5013 hemihydrate	Ligand for E3 Ligase Apoptosis	Cancer
Lenalidomide hemihydrate (CC-5013 hemihydrate) is a derivative of Thalidomide and an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-A0003

Lenalidomide CC-5013	Ligand for E3 Ligase Apoptosis	Cancer Inflammation/Immunology
Lenalidomide (CC-5013) is a derivative of Thalidomide and an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-A0003A

Lenalidomide hydrochloride CC-5013 hydrochloride	Ligand for E3 Ligase	Cancer Inflammation/Immunology
Lenalidomide hydrochloride (CC-5013 hydrochloride) is a derivative of Thalidomide and an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-14537

Latrepirdine dihydrochloride Dimebolin dihydrochloride	Amyloid-β Histamine Receptor Adrenergic Receptor 5-HT Receptor Autophagy	Neurological Disease Endocrinology
Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β (Aβ) secretion.

HY-B0976A

Fenoterol hydrobromide Fenoterol bromide; Th-1165a; Phenoterol hydrobromide	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Fenoterol hydrobromide is a β 2 adrenergic agonist designed to open up the airways to the lungs, is classed as sympathomimetic β2 agonist and asthma medication.

HY-103605

(S,R,S)-AHPC-C6-PEG3-C4-Cl VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; E3 ligase Ligand-Linker Conjugates 8	PROTAC	Cancer
(S,R,S)-AHPC-C6-PEG3-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-N0761

Isoferulic acid 3-Hydroxy-4-methoxycinnamic acid	Adrenergic Receptor Influenza Virus	Infection Endocrinology Metabolic Disease
Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is a cinnamic acid derivative that has antidiabetic activity. Isoferulic acid binds to and activates α1-adrenergic receptors (IC₅₀=1.4 µM) to enhance secretion of β-endorphin (EC₅₀=52.2 nM) and increase glucose use. Isoferulic acid also has anti-influenza virus activities.

HY-128975

m-Tyramine hydrobromide	Endogenous Metabolite	Neurological Disease
m-Tyramine hydrobromide is an endogenous trace amine neuromodulator. m-Tyramine hydrobromide has effects on the *adrenergic* and dopaminergic receptor^{[1, 2]}.

HY-U00117

Lusaperidone R107474	Adrenergic Receptor	Neurological Disease Endocrinology
Lusaperidone (R107474) is an α2 adrenergic receptor antagonist with K_is of 0.13 and 0.15 nM for α2A and α2C, respectively.

HY-130952

Thalidomide-O-C8-COOH	Ligand for E3 Ligase	Cancer
Thalidomide-O-C8-COOH is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-C8-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.

HY-17360

Tiotropium Bromide BA679 BR	mAChR	Neurological Disease
Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.

HY-136269

A 410099.1, amine-Boc hydrochloride	E3 Ligase Ligand-Linker Conjugate
A 410099.1, amine-Boc hydrochloride is a functionalized *IAP ligand* for PROTACs*. that is incorporates with an amine functional handle for ready conjugation to a linker/target protein ligand*.

HY-108652

α,β-Methylene ATP trisodium
Others Inflammation/Immunology

α,β-Methylene ATP trisodium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand.
HY-N1427A

Glycodeoxycholic acid monohydrate
Others Cancer

Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.
HY-104046

Octaaminocryptand 1
Others Others

Octaaminocryptand 1 is an aminocryptand ligand.

HY-102032A

(RS)-Butyryltimolol	Adrenergic Receptor	Others
(RS)-Butyryltimolol is the racemate of Butyryltimolol. Butyryltimolol, an effective prodrug of Timolol, improves the corneal penetration of Timolol. Butyryltimolol is a β-adrenergic blocker.

HY-B1111

Amitraz BTS-27419	Adrenergic Receptor Monoamine Oxidase Parasite	Infection Endocrinology
Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.

HY-111847

Androstanolone acetate	Androgen Receptor Ligand for Target Protein for PROTAC	Cancer
Androstanolone acetate is an androgen ligand, which targets androgen receptor (AR). Androstanolone acetate binds to cIAP1 ligand Bestatin via a linker to form PROTACs.

HY-100634

4-Hydroxypropranolol hydrochloride (±)-4-hydroxy Propranolol hydrochloride	Adrenergic Receptor	Neurological Disease
4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol. 4-Hydroxypropranolol hydrochlorid is of comparable potency to Propranolol. 4-Hydroxypropranolol hydrochlorid inhibits *β1- and β2-adrenergic* receptors with pA₂** values of 8.24 and 8.26, respectively. 4-Hydroxypropranolol hydrochlorid has intrinsic sympathomimetic activity, membrane stabilizing activity and potent antioxidant properties.

HY-17497A

Acebutolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Acebutolol hydrochloride is a *β1 adrenergic* receptor (β1AR)** antagonist. Acebutolol hydrochloride is used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.

HY-B1486

Oxprenolol hydrochloride Ba 39089	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable *β-adrenergic* receptor (β-AR) antagonist with a K_i of 7.10 nM in a radioligand binding assay using rat heart muscle.

HY-121251

BI-167107	Adrenergic Receptor	Cancer Neurological Disease Endocrinology
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant K_d of 84 pM.

HY-101918

DS-1040 Tosylate	Others	Cardiovascular Disease
DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC₅₀s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases.

HY-18728

STF-31
GLUT Autophagy Cancer

STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC₅₀ of 1μM^[1][2].
HY-113413

Imidazoleacetic acid
Imidazolyl-4-acetic acid
Endogenous Metabolite Metabolic Disease

Imidazoleacetic acid is an endogenous ligand that stimulates imidazole receptors.

HY-126457

Thalidomide-propargyl	Ligand for E3 Ligase	Cancer
Thalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-propargyl can be connected to the ligand for protein by a linker to form the IMiD containing PROTACs.

HY-119706

Barbadin	Others	Others
Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC₅₀ values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors.

HY-B0804S

Nadolol D9 SQ-11725 D9	Adrenergic Receptor	Endocrinology Cardiovascular Disease
Nadolol D9 (SQ-11725 D9) is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active *β-adrenergic* receptors** blocker.

HY-101690

QF0301B
Adrenergic Receptor Cardiovascular Disease Endocrinology

QF0301B is an α1 adrenergic receptor antagonist and a low α2 adrenoceptor, 5-HT2A, and histamine H1 receptor blocker.

HY-17497S

Acebutolol D7	Adrenergic Receptor	Endocrinology Cardiovascular Disease
Acebutolol D7 is a deuterium labeled Acebutolol. Acebutolol is a selective β1 adrenergic receptor antagonist used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.

HY-U00333

α1 adrenoceptor-MO-1	Adrenergic Receptor	Neurological Disease Endocrinology
α1 adrenoceptor-MO-1, an S enantiomer, has affinity at *alpha 1 adrenergic* receptor**, shows alphalytic activity, and possesses analgesic action; more active than R enantiomer.

HY-13715B

Norepinephrine bitartrate monohydrate Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate	Adrenergic Receptor Autophagy	Cardiovascular Disease Endocrinology
Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate) is a β₁-selective adrenergic receptor agonist with EC₅₀ of 5.37 μM.

HY-131103S

Phenylethanolamine A-D3	Adrenergic Receptor	Metabolic Disease Inflammation/Immunology
Phenylethanolamine A-D3 is a deuterium labeled Phenylethanolamine A. Phenylethanolamine A acts as a β-adrenergic agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.

HY-17453

Salmeterol xinafoate GR 33343X xinafoate	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol xinafoate is a long-acting beta-2 adrenergic receptor (β₂AR) agonist, with K_i of 1.5 nM for WT β₂AR, and used for asthma treatment.

HY-B0437

Sotalol hydrochloride MJ 1999	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Endocrinology
Sotalol hydrochloride (MJ 1999) is a non-selective competitive *β-adrenergic* receptor antagonist that also exhibits Class III antiarrhythmic properties by its inhibition of potassium channels**.

HY-136183

(S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride VH032 phenol-alkylC6-amine dihydrochloride	E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-phenol-alkylC6-amine (dihydrochloride) is a functionalized von-Hippel-Lindau (VHL) protein ligand for PROTAC. (S,R,S)-AHPC-phenol-alkylC6-amine incorporates an E3 ligase ligand plus an alkyl linker ready for conjugation to a target protein ligand.

HY-112797

Ds-HAPP
Others Others

Ds-HAPP is an anthrancenyl and dansyl fluorophore ligand.

HY-32329

Setiptiline Org-8282	5-HT Receptor Adrenergic Receptor	Neurological Disease
Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.

HY-131185

Pomalidomide-amido-C3-COOH	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-13951

ICI 118,551 hydrochloride ICI 118551 hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
ICI 118,551 (hydrochloride) is a highly selective *β2 adrenergic* receptor antagonist, with K_i**s of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.

HY-130737

Pomalidomide 4'-alkylC5-acid	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide 4'-alkylC5-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.

HY-103634

dFKBP-1
PROTAC FKBP Cancer

dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF of FKBP12, the Thalidomide based cereblon ligand and a linker.

HY-10349A

WAY-100635 Maleate	5-HT Receptor Dopamine Receptor	Neurological Disease
WAY-100635 maleate is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC₅₀ value of 0.91 nM and K_i value of 0.39 nM. WAY-100635 maleate has pIC₅₀ values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 maleate is also a potent dopamine D₄ receptor agonist.

HY-N0166

Gramine Donaxine	Adiponectin Receptor Adrenergic Receptor Reverse Transcriptase	Cancer Infection Metabolic Disease Endocrinology
Gramine (Donaxine) is a natural alkaloid isolated from giant reed, acts as an active adiponectin receptor (AdipoR) agonist, with IC₅₀s of 3.2 and 4.2 µM for AdipoR2 and AdipoR1, respectively. Gramine is also a human and mouse β2-Adrenergic receptor (β2-AR) agonist. Gramine (Donaxine) has anti-tumor, anti-viral and anti-inflammatory properties.

HY-136184

(S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride VH032-phenol-C4-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride is a functionalized von-Hippel-Lindau (VHL) protein ligand for PROTAC. (S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride incorporates an E3 ligase ligand plus an alkyl linker ready for conjugation to a target protein ligand.

HY-15238A

ST-836 hydrochloride
Dopamine Receptor Neurological Disease

ST-836 hydrochloride is a dopamine receptor ligand; Antiparkinsonian agent.
HY-15238

ST-836
Dopamine Receptor Neurological Disease

ST-836 is a dopamine receptor ligand; Antiparkinsonian agent.

HY-B0800

Guanethidine sulfate Guanethidine monosulfate	Others	Neurological Disease
Guanethidine sulfate (Guanethidine monosulfate) ia an antihypertensive agents. Guanethidine is also an adrenergic neurone blocking drug, enters noradrenergic nerve terminals by the neuronal amine carrier.

HY-23095

Thalidomide-5-OH	Ligand for E3 Ligase	Cancer
Thalidomide-5-OH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTACs.

HY-130708

UNC6852	Histone Methyltransferase PROTAC	Cancer
UNC6852 is a selective rolycomb repressive complex 2 (PRC2) degrader based on PROTAC and contains an EED (embryonic ectoderm development) ligand and a VHL ligand, with an IC₅₀ of 247 nM for EED.

HY-136237

Thalidomide-NH-C5-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C5-NH2 hydrochloride is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-136164

VH032-OH
Ligand for E3 Ligase Cancer

VH032-OH is the VH032-based VHL ligand. VH032-OH can be connected to the ligand for protein by a linker to form PROTACs.

HY-111879

Biotin-BS	SNIPER	Cancer
Biotin-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and biotin, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.

HY-130964B

Thalidomide-PEG4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-PEG4-NH2 hydrochloride is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-15583

Auristatin F	Microtubule/Tubulin ADC Cytotoxin	Cancer
Auristatin F is a potent cytotoxin. Auristatin F, a potent microtubule inhibitor and vascular damaging agent (VDA), can be used in antibody-drug conjugates (ADC).

HY-100583

(-)-(S)-Equol	Estrogen Receptor/ERR Endogenous Metabolite	Cancer Metabolic Disease Neurological Disease
(-)-(S)-Equol is a high affinity ligand for estrogen receptor β with a K_i of 0.73 nM.

HY-106547

Rilmazafone
GABA Receptor Neurological Disease

Rilmazafone is a benzodiazepine ω ligand with sedative and hypnotic effects.

HY-111878

BzNH-BS	SNIPER	Cancer
BzNH-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and benzoyl-amide, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.

HY-130639

Thalidomide-NH-C4-NH-Boc	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-NH-C4-NH-Boc (compound 15) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-129704

Thalidomide-NH-C6-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-NH-C6-NH2 is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-100634S

4-Hydroxypropranolol D7 hydrochloride (±)-4-hydroxy Propranolol D7 hydrochloride	Adrenergic Receptor	Neurological Disease
4-Hydroxypropranolol D7 hydrochloride ((±)-4-hydroxy Propranolol D7 hydrochloride) is a deuterium labeled 4-Hydroxypropranolol hydrochloride. 4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol, with potency comparable to Propranolol. 4-Hydroxypropranolol hydrochlorid inhibits *β1- and β2-adrenergic* receptors with pA₂** values of 8.24 and 8.26, respectively. 4-Hydroxypropranolol hydrochlorid has intrinsic sympathomimetic activity, membrane stabilizing activity and potent antioxidant properties.

HY-101514

β3-AR agonist 1	Adrenergic Receptor	Cardiovascular Disease Endocrinology
β3-AR agonist 1 (compound 15) is a highly potent, selective, and orally available β3-adrenergic receptor (β3-AR) agonist (EC₅₀=18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold).

HY-B0437AS

Sotalol D6 hydrochloride	Adrenergic Receptor Potassium Channel	Endocrinology Cardiovascular Disease
Sotalol D6 hydrochloride is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is a non-selective competitive *β-adrenergic* receptor antagonist that also exhibits Class III antiarrhythmic properties by its inhibition of potassium channels**.

HY-100300

AGN 192836	Adrenergic Receptor	Cardiovascular Disease Endocrinology
AGN 192836 is a potent and selective α2 adrenergic agonist with EC₅₀s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.

HY-129704A

Thalidomide-NH-C6-NH2 TFA	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-NH-C6-NH2 TFA is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-110392

CMP8	Estrogen Receptor/ERR	Cancer
CMP8, a selective ligand for estrogen receptor, binds to the mutant estrogen receptor ligand binding domain (ERLBD). CMP8 exhibits IC₅₀ values of 29 nM , 41 nM, 1100 nM and 2200 nM for MGERα, MGRERα, hERα and hERβ, respectively.

HY-136161

Pomalidomide-PEG6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.

HY-128767

VH032-PEG3-acetylene	E3 Ligase Ligand-Linker Conjugate	Cancer
VH032-PEG3-acetylene is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-75035

Calcipotriol Impurity C
VD/VDR Inflammation/Immunology

Calcipotriol Impurity C is the impurity of Calcipotriol, Calcipotriol is a ligand of VDR-like receptors.
HY-12452

DPN
Diarylpropionitrile
Estrogen Receptor/ERR Neurological Disease

DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor β(ER β) selective ligand.
HY-P0183

Nociceptin
Orphanin FQ
Opioid Receptor Neurological Disease

Nociceptin, a heptadecapeptide, is the endogenous ligand of the nociceptin receptor, acting as a potent anti-analgesic.

HY-107438A

Thalidomide-O-amido-C4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-136166

Thalidomide-NH-PEG3-propionic acid	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-NH-PEG3-propionic acid is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-130948B

Thalidomide-O-C4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C4-NH2 hydrochloride is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide (HY-14658) based cereblon ligand and a linker used in PROTAC technology.

HY-107439A

Thalidomide-O-amido-C8-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-C8-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-136156

Pomalidomide-PEG6-butyl iodide	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG6-butyl iodide is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.

HY-112618B

Thalidomide-O-amido-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-C6-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-131159

Thalidomide-O-C8-Boc	Ligand for E3 Ligase	Cancer
Thalidomide-O-C8-Boc is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-C8-Boc can be connected to the ligand for protein by a linker to form PROTACs.

HY-117071

Dabuzalgron Ro 115-1240	Adrenergic Receptor	Endocrinology Cardiovascular Disease
Dabuzalgron (Ro 115-1240) is an orally active and selective *α-1A adrenergic* receptor** agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.

HY-B0982

Pindolol LB-46	5-HT Receptor Adrenergic Receptor	Neurological Disease Endocrinology
Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (Ki=33nM).

HY-136162

Pomalidomide-PEG1-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology.

HY-122694A

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-114420

AP1867-2-(carboxymethoxy) PROTAC FKBP12-binding moiety 2	FKBP Ligand for Target Protein for PROTAC	Cancer
AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12^F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules.

HY-W011051

2-Arachidonoylglycerol
Cannabinoid Receptor Endogenous Metabolite Neurological Disease

2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
HY-U00228

Rilmazafone hydrochloride
450191S
GABA Receptor Neurological Disease

Rilmazafone hydrochloride (450191S) is a benzodiazepine ω ligand with sedative and hypnotic effects.
HY-15265

Impurity F of Calcipotriol
VD/VDR Cancer

Impurity F of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.

HY-P1205A

MCH(human, mouse, rat) TFA	MCHR1 (GPR24)	Neurological Disease
MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC₅₀ values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC₅₀ values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively.

HY-135572

TLX agonist 1	Others	Cancer Neurological Disease
TLX agonist 1 (ccrp2) is an orphan nuclear receptor tailless (TLX, NR2E1) modulator (EC₅₀=1μM; K_d= 650 nM). TLX agonist 1 potentiates TLX transcriptional repressive activity.

HY-U00244

Benzquinamide P2647; BZQ; Benzoquinamide	Adrenergic Receptor	Metabolic Disease Endocrinology
Benzquinamide (P2647) is an antiemetic which can bind to the α_2A, α_2B, and α_2C adrenergic receptors (α2-AR) with K_i values of 1,365, 691, and 545 nM, respectively.

HY-133144

Lenalidomide-OH	Ligand for E3 Ligase	Cancer
Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 (HY-133137).

HY-130981

FN-1501-propionic acid	CDK Ligand for Target Protein for PROTAC	Cancer
FN-1501-propionic acid is a CDK2/9 ligand for PROTAC. FN-1501-propionic acid and a CRBN ligand have been used to design PROTAC CDK2/9 degrader (HY-130709).

HY-112599B

Pomalidomide-PEG4-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in the synthesis of PROTACs..

HY-110399

Cirsiliol
Lipoxygenase Neurological Disease

Cirsiliol is a potent and selective 5-lipoxygenase inhibitor and a competitive low affinity benzodiazepine receptor ligand.
HY-111663

VL285
Ligand for E3 Ligase Cancer

VL285 is a potent VHL ligand with an IC₅₀ of 0.34 μM.
HY-13723

Pimecrolimus
SDZ-ASM 981
Others Inflammation/Immunology

Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12.
HY-N0277

Aconine
Jesaconine
NF-κB Inflammation/Immunology Cancer

Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.

HY-122470

Stampidine	Reverse Transcriptase HIV	Infection
Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLV_IIIB (B-envelope subtype) and primary clinical isolates with IC₅₀s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC₅₀s of 8.7 nM and 11.2 nM, respectively.

HY-114176B

(S,R,S)-AHPC-C4-NH2 dihydrochloride VH032-C4-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C4-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.

HY-122710A

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-107442

PROTAC BRD4-binding moiety 1	Epigenetic Reader Domain Ligand for Target Protein for PROTAC	Cancer
PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136).

HY-114176A

(S,R,S)-AHPC-C4-NH2 VH032-C4-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.

HY-136165

(S,R,S)-AHPC-PEG3-propionic acid	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG3-propionic acid is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

HY-122825

SNIPER(ER)-110	SNIPER Estrogen Receptor/ERR	Cancer
SNIPER(ER)-110 consists of a cIAP1 ligand and an estrogen ligand, connected by a linker. SNIPER(ER)-51 induces estrogen receptor (ER) protein degradation with DC₅₀s of <3 nM and 7.7 nM after 4 h and 48 h, respectively.

HY-101755

Tedatioxetine hydrobromide Lu AA 24530 hydrobromide	5-HT Receptor Adrenergic Receptor	Neurological Disease Endocrinology
Tedatioxetine hydrobromide acts as a triple reuptake inhibitor and 5-HT_2A, 5-HT_2C, 5-HT₃ and α_1A-adrenergic receptor antagonist.

HY-114434

AP1867
FKBP Cancer

AP1867 is a synthetic FKBP12^F36V-directed ligand.
HY-100486

BTTAA
Others Others

BTTAA is a Cu(I)-stabilizing ligand, whch performs potently with ubiquitin Glu18AzF.
HY-135324

4,4'-Iminodiphenol
Estrogen Receptor/ERR Endocrinology

4-Propionamidophenol (compound 4a) is an inactive estrogen receptor ligand based on the diphenylamine skeleton.
HY-116677

Tris(benzyltriazolylmethyl)amine
TBTA
Others Others

Tris(benzyltriazolylmethyl)amine (TBTA) is a ligand that acts as a biochemical tool for the tagging of proteins and enzymes.
HY-B1033

Metergoline
5-HT Receptor Neurological Disease

Metergoline is a psychoactive drug of the ergoline chemical class which acts as a ligand for various serotonin and dopamine receptors.

HY-130648

Thalidomide-NH-PEG7	Drug-Linker Conjugates for ADC	Cancer
Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.

HY-43722

Lenalidomide-Br	Ligand for E3 Ligase	Cancer
Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-Br can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC STAT3 degrader SD-36 (HY-129602).

HY-129703B

Thalidomide-NH-PEG2-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-107440A

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-129703

Thalidomide-NH-PEG2-C2-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-130269

β-Naphthoflavone-CH2-OH β-NF-CH2-OH	Ligand for E3 Ligase	Cancer
β-Naphthoflavone-CH2-OH (β-NF-CH2-OH) is a ligand for arylhydrocarbon receptor (AhR) E3 ligase. β-Naphthoflavone-CH2-OH can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs (e.g., β-naphthoflavone-JQ1) that recruit the AhR E3 ligase complex by incorporating AhR ligands into chimeric molecules. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-19945

DAA-1106	GABA Receptor	Neurological Disease
DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), as a potent and selective agonist at the peripheral benzodiazepine receptor.

HY-15527

Emapunil
AC-5216; XBD-173
Others Neurological Disease

Emapunil(AC-5216;XBD-173) is a translocator protein [TSPO (18 kDa)] ligand.
HY-32339

Maxacalcitol
22-Oxacalcitriol
VD/VDR Metabolic Disease

Maxacalcitol (22-Oxacalcitriol) is non-calcemic vitamin D3 analog and ligand of VDR-like receptors.

HY-U00250

β-Amino Acid Imagabalin Hydrochloride PD-0332334	Calcium Channel	Neurological Disease
β-Amino Acid Imagabalin Hydrochloride (PD-0332334) is a ligand for the α2δ subunit of the voltage-dependent calcium channel.

HY-101601

Bamirastine TAK-427	Histamine Receptor	Inflammation/Immunology Endocrinology
Bamirastine inhibits ligand binding to recombinant human histamine H₁ receptors (rhH₁R) with an IC₅₀ value of 17.3 nM.

HY-100034

NSC 663284 DA-3003-1	Phosphatase Histone Methyltransferase	Cancer
NSC 663284 is a potent, cell-permeable, and irreversible Cdc25 dual specificity phosphatase inhibitor, has an IC₅₀ for Cdc25B2 of 0.21 μM. NSC 663284 exhibits mixed competitive kinetics against Cdc25A, Cdc25B(2), and Cdc25C with Ki values of 29, 95, and 89 nM, respectively. NSC 663284 inhibits NSD2 (IC₅₀ of 170 nM) through a direct interaction with the catalytic SET domain (K_d of 370 nM).

HY-P1380A

Difopein TFA	Apoptosis	Cancer
Difopein (TFA), a specific and competitive inhibitor of 14-3-3 protein (a highly conserved eukaryotic regulatory molecule), blocking the ability of 14-3-3 to bind to target proteins and inhibits 14-3-3/Ligand interactions. Difopein (TFA) leads to induction of apoptosis and enhances the ability of cisplatin to kill cells.

HY-129703A

Thalidomide-NH-PEG2-C2-NH2 TFA	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-131190

N-Boc-SBP-0636457-O-C3-COOH	E3 Ligase Ligand-Linker Conjugate	Cancer
N-Boc-SBP-0636457-OH is a synthesized E3 ligase ligand-linker conjugate that incorporates IAP ligand and a linker. N-Boc-SBP-0636457-OH can be used to design a PROTAC Bcl-xL degrader-1 (HY-131188).

HY-69220

7-Octynoic acid	PROTAC Linker	Cancer
7-Octynoic acid (compound 42) is a PROTAC linker and can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-101861

Miridesap CPHPC; Ro63-8695; GSK2315698	Others	Neurological Disease
Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles.

HY-17571

Oxytocin α-Hypophamine; Oxytocic hormone	Oxytocin Receptor	Endocrinology
Oxytocin (α-Hypophamine) is a mammalian neurohypophysial hormone; its actions are mediated by specific, high-affinity oxytocin receptors; ligand of oxytocin receptor.

HY-17571A

Oxytocin acetate α-Hypophamine acetate; Oxytocic hormone acetate	Oxytocin Receptor	Endocrinology
Oxytocin acetate (α-Hypophamine acetate) is a mammalian neurohypophysial hormone; its actions are mediated by specific, high-affinity oxytocin receptors; ligand of oxytocin receptor.

HY-15264

MC 1046 Impurity A of Calcipotriol	VD/VDR	Cancer
MC 1046(Impurity A of Calcipotriol) is an impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.

HY-11007

GNF-2
Bcr-Abl SARS-CoV Cancer

GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC₅₀ of 138 nM .

HY-100290

5-HT1A modulator 1	5-HT Receptor	Neurological Disease
5-HT1A modulator 1 displays very high affinities for the 5HT_1A, adrenergic α₁ and dopamine D₂ receptor with IC₅₀s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively.

HY-128128

ASN04421891	Others	Neurological Disease
ASN04421891 is a potent GPR17 receptor modulator, with an EC₅₀ of 3.67 nM in [35S]GTPγS binding assay. ASN04421891 can be used for neurodegenerative diseases research.

HY-18370

HIF-2α-IN-3	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α (HIF-2α), exhibits an IC₅₀ of 0.4 µM and a K_D of 1.1 µM. Anticancer agent.

HY-108258A

PSN 375963 hydrochloride	GPR119	Endocrinology
PSN 375963 hydrochloride is a potent GPR119 agonist, with EC₅₀s of 8.4 and 7.9 μM for human and mouse GPR119, respectively. PSN 375963 hydrochloride shows similar potency to the endogenous agonist oleoylethanolamide (OEA).

HY-130197

Lipoamido-PEG4-azide
PROTAC Linker Cancer

Lipoamido-PEG4-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

HY-125845A

(S,S,S)-AHPC hydrochloride (S,S,S)-VH032-NH2 hydrochloride	Ligand for E3 Ligase	Cancer
(S,S,S)-AHPC hydrochloride is a von Hippel-Lindau (VHL) amino building block. (S,S,S)-AHPC is a ligand used as a negative control for (S,R,S)-AHPC. (S,R,S)-AHPC is the VH032-based VHL ligand used in the recruitment of the VHL protein.

HY-131189

N-Boc-SBP-0636457-OH	Ligand for E3 Ligase	Cancer
N-Boc-SBP-0636457-OH, a ligand for E3 ubiquitin ligase, is used in the recruitment of IAP E3 ligases. N-Boc-SBP-0636457-OH can be connected to the ligand for Bcl-xL by a linker to form PROTAC Bcl-xL degrader-1 (HY-131188).

HY-130849

(S,R,S)-AHPC-Me-C5-COOH	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-Me-C5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C5-COOH can be used in PROTAC DT2216 (HY-130604).

HY-131186

Pomalidomide-amido-C3-piperazine-N-Boc	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).

HY-112398

GSK1379725A
Epigenetic Reader Domain Others

GSK1379725A is a selective BPTF ligand with a K_d of 2.8 uM, showing no binding activity for Brd4.
HY-111850

Bestatin-amido-Me
PROTAC IAP binding moiety 1
Ligand for E3 Ligase Cancer

Bestatin-amido-Me, the Bestatin-based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.
HY-P2267

LDV
Integrin

LDV, a non-fluorescent derivative of LDV FITC, is a α4β1 integrin (VLA-4) ligand (K_d ~ 12 nM).
HY-100275

MK-3328
Amyloid-β Neurological Disease

MK-3328 is a β-Amyloid PET ligand, which exhibits high binding potency with an IC₅₀ of 10.5 nM.

HY-15266

24R-Calcipotriol PRI 2202; Impurity D of Calcipotriol	VD/VDR	Cancer
24R-Calcipotriol(PRI 2202) is an impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.

HY-114208

BI-9321	Histone Methyltransferase	Cancer
BI-9321 is a potent, selective and cellular active *nuclear receptor-binding SET* domain 3 (NSD3)-PWWP1 domain antagonist with a K_d value of 166 nM. BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC₅₀** of 1.2 μM in U2OS cells.

HY-114208A

BI-9321 trihydrochloride	Histone Methyltransferase	Cancer
BI-9321 trihydrochloride is a potent, selective and cellular active *nuclear receptor-binding SET* domain 3 (NSD3)-PWWP1 domain antagonist with a K_d value of 166 nM. BI-9321 trihydrochloride is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 trihydrochloride specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC₅₀** of 1.2 μM in U2OS cells.

HY-130641

Br-C10-methyl ester	PROTAC Linker	Cancer
Br-C10-methyl ester is a PROTAC linker, which refers to the alkyl/ether composition. Br-C10-methyl ester is used in the synthesis of a series of PROTACs (MS432). PROTACs contain two different ligands connected by a linker; one is the VHL ligand portion and the other is for the target protein.

HY-107444

PROTAC Her3-binding moiety 1
Ligand for Target Protein for PROTAC Cancer

PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC.

HY-A0077AS

Perphenazine D8 Dihydrochloride	5-HT Receptor Adrenergic Receptor Dopamine Receptor Histamine Receptor	Endocrinology Neurological Disease
Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).

HY-10349

WAY-100635	5-HT Receptor Dopamine Receptor	Neurological Disease
WAY-100635 is a potent and selective 5-HT_1A Receptor antagonist with a pIC₅₀ of 8.87, an apparent pA₂ of 9.71. WAY-100635 is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC₅₀ value of 0.91 nM and K_i value of 0.39 nM. WAY-100635 has pIC₅₀ values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 is also a potent dopamine D₄ receptor agonist.

HY-129941

(S,R,S)-AHPC-C10-NH2 VH032-C10-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.

HY-129941A

(S,R,S)-AHPC-C10-NH2 dihydrochloride VH032-C10-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-C10-NH2 dihydrochloride) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.

HY-131231

Thalidomide-NH-PEG3-CH2CHO	Ligand for E3 Ligase	Cancer
Thalidomide-NH-PEG3-CH2CHO is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-NH-PEG3-CH2CHO can be connected to the ligand for protein by a linker to form PROTAC BCL-XL degrader XZ739 (HY-133557).

HY-130854

Thalidomide-NH-C6-NH-Boc	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-NH-C6-NH-Boc is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and a linker used for MI-389 (compound 22) synthesis. MI-389 is a potent phthalimide PROTAC degrader based on the multi-targeted receptor tyrosine kinase inhibitor sunitinib (HY-10255A).

HY-130847

(S,R,S)-AHPC-Me-C10-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-Me-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C10-NH2 can be used in PROTAC MS432 (HY-130602).

HY-P1186

Eledoisin Related Peptide Eledoisin-Related Peptide; Eledoisin RP	Neurokinin Receptor	Neurological Disease
Eledoisin Related Peptide is a Substance P analog that excites neurons and triggers behavioral responses. Eledoisin Related Peptide is also a tachykinin receptor ligand.

HY-16785

Veledimex INXN-1001; RG-115932	Interleukin Related Cytochrome P450	Inflammation/Immunology Cancer
Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.

HY-16785A

Veledimex racemate INXN-1001 racemate; RG-115932 racemate	Interleukin Related Cytochrome P450	Cancer Inflammation/Immunology
Veledimex racemate (INXN-1001 racemate) is the racemate of veledimex. Veledimex is an orally available, small-molecule activator ligand for the RheoSwitch Therapeutic System.

HY-P0031

Cyclo(RADfK)
Integrin Others

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

HY-P1037

Motilin (26-47), human, porcine	Motilin Receptor	Others
Motilin (26-47), human, porcine is an endogenous motilin receptor ligand with K_i and EC₅₀ of 2.3 nM and 0.3 nM in a Chinese hamster ovary cell line.

HY-B0804

Nadolol SQ-11725	Adrenergic Receptor	Cardiovascular Disease
Nadolol (SQ-11725) is a non-selective and orally active *β-adrenergic* receptors** blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research.

HY-N2388

Auraptene	MMP	Inflammation/Immunology Cancer
Auraptene is the most abundant naturally occurring geranyloxycoumarin. Auraptene is primarily isolated from plants in the Rutaceae family, such as citrus fruits. Auraptene decreases the secretion of matrix metalloproteinase 2 (MMP-2) as well as key inflammatory mediators, including IL-6, IL-8, and chemokine (C-C motif) ligand-5(CCL5).

HY-130853

Thalidomide-NH-PEG2-C2-NH-Boc	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Thalidomide based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis. dBRD9 is a selective BRD9 probe PROTAC degrader for the study of BAF complex biology.

HY-111844

PROTAC RAR Degrader-1	SNIPER PROTAC RAR/RXR	Cancer
PROTAC RAR Degrader-1 comprises a cIAP1 ligand binding group, a linker and a RAR ligand binding group. PROTAC RAR Degrader-1 is an RAR degrader. Maximal RAR degradation at 30 μM concentration in HT1080 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).

HY-103603B

(S,R,S)-AHPC-PEG2-NH2 dihydrochloride VH032-PEG2-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-PEG2-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.

HY-10121

Asenapine Org 5222	5-HT Receptor Adrenergic Receptor	Neurological Disease Endocrinology
Asenapine(Org 5222) inhibits adrenergic receptor (α1, α2A, α2B, α2C) with Ki of 0.25-1.2 nM and also inhibits 5-HT receptor (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) with Ki of 0.03-4.0 nM.

HY-111872

SNIPER(ABL)-020
SNIPER Bcr-Abl Cancer

SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.

HY-111857

Dasatinib carbaldehyde BMS-354825 carbaldehyde; PROTAC ABL binding moiety 4	Ligand for Target Protein for PROTAC	Cancer
Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

HY-112895A

(R)-UT-155
Androgen Receptor Cancer

(R)-UT-155 (compound 11) is a selective androgen receptor degrader (SARD) ligand. Less active than the S-isomer.

HY-110385

cGAMP disodium Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium	Endogenous Metabolite	Inflammation/Immunology
cGAMP disodium (Cyclic GMP-AMP disodium) is the third cyclic dinucleotide (CDN) to be discovered in bacteria. cGAMP disodium is an effective adjuvant for sublingual vaccination capable of promoting broad immunity including serum anti-PA neutralizing and anti-PA SIgA responses in airway secretions.

HY-34544

2-Hexylthiophene	Others	Others
2-Hexylthiophene is an extremely weak basic heteroaromatic compound. 2-Hexylthiophene can be used to modify and improve the molar absorption coefficient of ruthenium sensitizer

HY-130988

Ipatasertib-NH2 GDC-0068-NH2; RG7440-NH2	Ligand for Target Protein for PROTAC	Cancer
Ipatasertib-NH2 (GDC-0068-NH2;RG7440-NH2) is a ligand for target protein AKT for PROTAC, binds to lenalidomide, a ligand of ubiquitin E3 ligase cereblon (CRBN), via a ten-hydrocarbon linker to form INY-03-041 (HY-133120) to degrade AKT.

HY-P9904

Atezolizumab
MPDL3280A
PD-1/PD-L1 Cancer

Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-15420

BML-190 Indomethacin morpholinylamide; IMMA	Cannabinoid Receptor	Cancer
BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).

HY-A0007

Rotigotine Hydrochloride N-0923 Hydrochloride	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease
Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the *α2B-adrenergic* receptor, with K_i** of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-130715

tert-Butyl 11-aminoundecanoate	PROTAC Linker	Cancer
tert-Butyl 11-aminoundecanoate (compound 6b) is a PROTAC linker, which refers to the PEG composition. tert-Butyl 11-aminoundecanoate can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-111858

SNIPER(ABL)-050
SNIPER Bcr-Abl Cancer

SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.

HY-111852

GNF5-amido-Me PROTAC ABL binding moiety 2	Ligand for Target Protein for PROTAC	Cancer
GNF5-amido-Me, the GNF5 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.

HY-111853

MV-1-NH-Me
PROTAC IAP binding moiety 2
Ligand for E3 Ligase Cancer

MV-1-NH-Me, the MV-1 based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.

HY-13751

SR-31747	Sigma Receptor	Inflammation/Immunology
SR-31747 is a sigma ligand with immunosuppressive and anti-inflammatory properties. SR-31747 blocks cell proliferation by inhibiting sterol isomerase.

HY-122577

EN40
Aldehyde Dehydrogenase (ALDH) Cancer

EN40 is a potent, selective aldehyde dehydrogenase 3A1 (ALDH3A1) inhibitor as a covalent ligand, exhibits an IC₅₀ value of 2 uM
HY-124625

BI-4464
FAK Ligand for Target Protein for PROTAC Cancer

BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC₅₀ of 17 nM. A PTK2 ligand for PROTAC.

HY-A0077

Perphenazine	5-HT Receptor Adrenergic Receptor Dopamine Receptor Histamine Receptor	Neurological Disease Endocrinology
Perphenazine is a typical antipsychotic drug, inhibits *5-HT_2Areceptor, Alpha-1A adrenergic* receptor, Dopamine receptor D2/D3, D2L receptor, and Histamine H1 receptor, with K_i** values of 5.6, 10, 0.765/0.13, 3.4, and 8 nM, respectively.

HY-129774

Phthalimide-PEG4-MPDM-OH	PROTAC Linker	Cancer
Phthalimide-PEG4-MPDM-OH is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG4-MPDM-OH can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-130617

Pomalidomide-amido-C1-Br	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-amido-C1-Br is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758). PROTAC B-Raf degrader 1 has anti-cancer activity.

HY-129773

Phthalimide-PEG4-PDM-OTBS	PROTAC Linker	Cancer
Phthalimide-PEG4-PDM-OTBS is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG4-PDM-OTBS can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-N4194

Glabrone	PPAR	Metabolic Disease
Glabrone is an isoflavone isolated from Glycyrrhiza glabra roots. Glabrone exhibits anti-influenza activity and significant PPAR-γ ligand-binding activity.

HY-B2087

Glycerol phenylbutyrate HPN-100	Sigma Receptor	Cardiovascular Disease
Glycerol phenylbutyrate is a sigma-2 (σ2) receptor ligand, with a pK_i of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.

HY-129405

N-(Ketocaproyl)-D,L-homoserine lactone	Bacterial	Infection
N-(Ketocaproyl)-D,L-homoserine lactone is a natural, very active ligand of LuxR. N-(Ketocaproyl)-D,L-homoserine lactone is a quorum sensing (QS) autoinducer.

HY-111413

c(phg-isoDGR-(NMe)k)
Integrin Cancer

c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC₅₀ of 2.9 nM.

HY-111849

Imatinib carbaldehyde CGP-57148B carbaldehyde; STI571 carbaldehyde; PROTAC ABL binding moiety 1	Ligand for Target Protein for PROTAC	Cancer
Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.

HY-13956

Pioglitazone U 72107	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-15329

Maxacalcitol-D6	VD/VDR	Metabolic Disease
Maxacalcitol-D6 is the deuterated form of Maxacalcitol (22-Oxacalcitriol), which is a non-calcemic vitamin D3 analog and VDR ligand of VDR-like receptors.

HY-111851

SNIPER(ABL)-049	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 100 μM.

HY-136055

(S,R,S)-AHPC-C5-COOH VH032-C5-COOH	E3 Ligase Ligand-Linker Conjugate HIF/HIF Prolyl-Hydroxylase	Cancer
(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized *E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand* and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL/HIF-1α interaction with a K_d of 185 nM, has the potential for the study of anemia and ischemic diseases.

HY-75502

Rotigotine N-0437; N-0923	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease Endocrinology
Rotigotine (N-0437; N-0923) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the *α2B-adrenergic* receptor, with K_i**s of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-101300

Cirazoline hydrochloride LD 3098 hydrochloride	Adenosine Receptor	Neurological Disease
Cirazoline hydrochloride (LD 3098 hydrochloride) is a potent competitive full α1A-adrenergic receptor (α1A-AR) agonist (K_i=120 nM) and only a partial agonist at α1B-AR (K_i= 960 nM) and α1D-AR (K_i=660 nM).

HY-A0072S

Zilpaterol-d7	Adrenergic Receptor
Zilpaterol-d7 is a deuterium labeled Zilpaterol. Zilpaterol is a *β-adrenergic* receptor** agonist that putatively, through activation of protein kinase A, increases protein synthesis in skeletal muscle fibers as well as reduces lipogenesis and increases lipolysis in adipose tissues. Formulations containing Zilpaterol have been used to increase lean body weight and improve feed efficiency in commercial beef cattle.

HY-A0019

Paliperidone 9-Hydroxyrisperidone	Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Neurological Disease
Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia.

HY-P0272

Peptide T
HIV Infection

Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

HY-107447

N-Deshydroxyethyl Dasatinib N-Deshydroxyethyl BMS-354825	Ligand for Target Protein for PROTAC	Cancer
N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL.

HY-U00180

KF21213	Adenosine Receptor	Neurological Disease
KF21213 is a highly selective ligand for mapping CNS adenosine A_2A receptors. KF21213 shows a high affinity for the adenosine A_2A receptors (K_i=3.0 nM).

HY-136280

Panamesine EMD 57445	Sigma Receptor	Neurological Disease
Panamesine (EMD 57445) is a sigma receptor ligand, which has a high affinity (IC₅₀ 6 nM) and selectivity for sigma binding sites. Panamesine is a potential atypical neuroleptic agent.

HY-111860

SNIPER(ABL)-013	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 20 μM.

HY-111413A

c(phg-isoDGR-(NMe)k) TFA
Integrin Cancer

c(phg-isoDGR-(NMe)k) TFA is a selective and potent α5β1-integrin ligand with an IC₅₀ of 2.9 nM.

HY-13751A

SR-31747 free base	Sigma Receptor	Inflammation/Immunology
SR-31747 free base is a sigma ligand with immunosuppressive and anti-inflammatory properties. SR-31747 blocks cell proliferation by inhibiting sterol isomerase.

HY-130640

(S,R,S)-AHPC-Me-C7 ester
E3 Ligase Ligand-Linker Conjugate Cancer

(S,R,S)-AHPC-Me-C7 ester is a E3 ligase ligand-linker conjugate used to synthesise BCL-X_L PROTAC degraders.

HY-P1123

MEDICA16	ATP Citrate Lyase GPR40 GPR120	Metabolic Disease
MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120.

HY-129364

5-A-RU hydrochloride 5-Amino-6-(D-ribitylamino)uracil hydrochloride	Others	Inflammation/Immunology
5-A-RU hydrochloride (5-Amino-6-(D-ribitylamino)uracil hydrochloride), a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU hydrochloride forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways.

HY-P0023

Cyclo(-RGDfK)	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.

HY-P1299A

UFP-101 TFA	Opioid Receptor	Neurological Disease
UFP-101 TFA is a potent, selective, and competitive antagonist of the NOP receptor, with a pK_i of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect.

HY-120738

p-MPPI hydrochloride	5-HT Receptor	Neurological Disease
p-MPPI hydrochloride is a selective 5-HT1A receptor antagonist with high affinity for 5-HT1A receptors. p-MPPI hydrochloride can crosses the blood-brain barrier, and has clear antidepressant and anxiolytic-like effects.

HY-P1299

UFP-101	Opioid Receptor	Neurological Disease
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pK_i of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect.

HY-P0023A

Cyclo(-RGDfK) TFA	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.

HY-129364A

5-A-RU 5-Amino-6-(D-ribitylamino)uracil	Others	Inflammation/Immunology
5-A-RU (5-Amino-6-(D-ribitylamino)uracil), a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways.

HY-12436

NTRC-824	Neurotensin Receptor	Neurological Disease
NTRC-824 (Compound 5) is a potent, selective and neurotensin-like nonpeptide neurotensin receptor type 2 (NTS2) antagonist with an IC₅₀ of 38 nM and a K_i of 202 nM. NTRC-824 is >150-fold selectivity for NTS2 over NTS1 (K_i >30 μM).

HY-129772

Phthalimide-PEG3-C2-OTs	PROTAC Linker	Cancer
Phthalimide-PEG3-C2-OTs (Compound 5) is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG3-C2-OTs can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-129619

SNIPER(ER)-87	SNIPER Estrogen Receptor/ERR	Cancer
SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the ERα protein (IC₅₀=0.097 μM). SNIPER(ER)-87 preferentially recruits XIAP to ERα in the cells, and XIAP is the primary E3 ubiquitin ligase responsible for the SNIPER(ER)-87-induced ERα degradation.

HY-P0272A

Peptide T TFA	HIV	Infection
Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

HY-15594

Phen-DC3
DNA/RNA Synthesis Cancer

Phen-DC3 is a G-quadruplex (G4) specific ligand which can inhibit FANCJ and DinG helicases with IC₅₀s of 65±6 and 50±10 nM, respectively.

HY-15043

ELN-441958	Bradykinin Receptor	Cancer Endocrinology
ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM.

HY-111855

HG-7-85-01-Decyclopropane PROTAC ABL binding moiety 3	Ligand for Target Protein for PROTAC	Cancer
HG-7-85-01-Decyclopropane, the HG-7-85-01 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

HY-111859

SNIPER(ABL)-058	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 10 μM.

HY-111854

SNIPER(ABL)-015	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 5 μM .

HY-100935S

Cimaterol-D7	Adrenergic Receptor
Cimaterol-D7 is the deuterium labeled Cimaterol. Cimaterol is a potent agonist of β-adrenergic receptors (pEC₅₀s=8.13, 8.78, and 6.62 for human β1, β2, and β3, respectively). Cimaterol has been used in farmed animals to increase carcass mass and to alter muscle and fat deposition.

HY-15394

(Rac)-Rotigotine hydrochloride	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Endocrinology Neurological Disease
(Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_is of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-122537A

Arotinolol	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
Arotinolol is a nonselective *α/β-adrenergic* receptor blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent** for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases.

HY-102023

GNF351	Aryl Hydrocarbon Receptor	Others
GNF351 is a full aryl hydrocarbon receptor (AHR) antagonist. GNF351 competes with a photoaffinity AHR ligand for binding to the AHR with an IC₅₀ of 62 nM. GNF351 is minimal toxicity in mouse or human keratinocytes.

HY-130852

CDK9-IN-11
CDK Ligand for Target Protein for PROTAC Cancer

CDK9-IN-11 is a potent CDK9 inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628).

HY-106025

Radequinil AC-3933	GABA Receptor	Neurological Disease
Radequinil (AC-3933) is a benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 binds to GABA(-) and GABA(+) ligand with K_is of 5.15 and 6.11 nM, respectively.

HY-N6253

Pinoresinol (+)-Pinoresinol	Apoptosis	Cancer
Pinoresinol is a lignol of plant origin serving for defense in a caterpillar. Pinoresinol drastically sensitizes cancer cells against TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis.

HY-15594A

Phen-DC3 Trifluoromethanesulfonate Phen-DC3 Triflate	G-quadruplex	Cancer
Phen-DC3 Trifluoromethanesulfonate is a G-quadruplex (G4) specific ligand which can inhibit FANCJ and DinG helicases with IC₅₀s of 65±6 and 50±10 nM, respectively.

HY-114306

EC0489	Antifolate	Cancer
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor. Small molecule-drug conjugate (SMDC).

HY-111873

SNIPER(ABL)-019	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 0.3 μM.

HY-130850

CDK9-IN-10
CDK Ligand for Target Protein for PROTAC Cancer

CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811).

HY-40178

NH2-C4-NH-Boc	PROTAC Linker	Cancer
NH2-C4-NH-Boc (compound 15) is a PROTAC linker, which refers to the Alkyl/ether composition. NH2-C4-NH-Boc can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-108496

Sphingosine-1-phosphate S1P	Endogenous Metabolite LPL Receptor	Endocrinology
Sphingosine-1-phosphate (S1P) is an agonist of S1P_1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca²⁺ as an extracellular ligand for G protein-coupled receptors. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids.

HY-111861

SNIPER(ABL)-024	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 5μM.

HY-P0224

N-Formyl-Met-Leu-Phe fMLP; N-Formyl-MLF	TNF Receptor	Inflammation/Immunology
N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.

HY-130845

AR antagonist 1	Ligand for E3 Ligase	Cancer
AR antagonist 1 (compound 29) is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020).

HY-100686

U93631	GABA Receptor	Neurological Disease
U93631 is a GABAA receptor ligand of novel chemical structure with IC50 of 100 nM,and has been shown to induce a rapid, time-dependent decay of GABA-induced whole-cell Cl-currents in recombinant GABAA receptors.

HY-129652

Halo PROTAC 1	PROTAC Autophagy	Cancer
Halo PROTAC 1 is a PROTAC, which is a ligand having activity to bind to an intracellular proteins fused with HaloTag and a structure having activity to induce autophagy of an intracellular molecule are linked via a PEG linker.

HY-124673

AF40431	Neurotensin Receptor	Neurological Disease
AF40431, the first reported small-molecule ligand of sortilin, has an IC₅₀ of 4.4 µM and a K_d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilin.

HY-111862

SNIPER(ABL)-044	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 10 μM.

HY-135345

PROTAC FKBP Degrader-3	PROTAC FKBP	Cancer
PROTAC FKBP Degrader-3 is a PROTAC that comprises a FKBP ligand binding group, a linker and an VHL binding group. PROTAC FKBP Degrader-3 is a potent FKBP degrader.

HY-13992

AP20187 B/B Homodimerizer	FKBP	Metabolic Disease
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.

HY-112617B

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker, can be an immunomodulater for the treatment of cancer.

HY-16785B

Veledimex (S enantiomer) INXN-1001 (S enantiomer); RG-115932 (S enantiomer)	Interleukin Related Cytochrome P450	Cancer
Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.

HY-101622

5-HT6/7 antagonist 1	5-HT Receptor Dopamine Receptor
5-HT6/7 antagonist 1 is a multifunctional ligand that antagonizes 5-HT6/7/2A and D2 receptors, without interacting with M1 receptors and hERG channels.

HY-13943

CNX-774	Btk	Cancer
CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.

HY-101026

CCT251236	HSP	Cancer
CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC₅₀ of 19 nM for inhibition of HSF1-mediated HSP72 induction.

HY-P1125

4-CMTB
Others Others

4-CMTB is a selective free fatty acid receptor 2 (FFA2/GPR43) agonist and a positive allosteric modulator (pEC₅₀=6.38).

HY-121295

Roseoflavin	Bacterial	Infection
Roseoflavin, a natural pigment originally isolated from Streptomyces davawensis, is an antimetabolite analog of Riboflavin and flavin mononucleotide that has antimicrobial properties.

HY-103110A

ST1936 oxalate	5-HT Receptor	Neurological Disease
ST1936 oxalate is a selective, nanomolar affinity 5-HT₆ receptor agonist with K_i values of 13 nM, 168 nM and 245 nM for human 5-HT₆, 5-HT₇ and 5-HT_2B receptors, respectively. ST1936 oxalate also shows moderate affinity (Ki of 300 nM) for *human α2 adrenergic* receptor**.

HY-130618

Boc-C1-PEG3-C4-OH	PROTAC Linker	Cancer
Boc-C1-PEG3-C4-OH is a PROTAC linker, which refers to the Alkyl/ether composition. Boc-C1-PEG3-C4-OH can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-19567

PK 11195 RP 52028	Parasite	Infection
PK 11195 (RP 52028) is a ligand of translocator protein (TSPO), which targets Leishmania chemotherapy, with IC₅₀s of 14.2 μM, 8.2 μM, 3.5 μM for L. amazonensis, L. major and L. braziliensis, respectively.

HY-111863

SNIPER(ABL)-047	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 2 μM.

HY-123937

THAL-SNS-032	PROTAC CDK	Cancer
THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).

HY-130714

TD-165	PROTAC	Cancer
TD-165 is a PROTAC-based cereblon (CRBN) degrader. TD-165 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group.

HY-108477

TMPyP4 tosylate TMP 1363	G-quadruplex Telomerase	Cancer
TMPyP4 tosylate (TMP 1363) is a quadruplex-specific ligand, which inhibits the interaction between G-quadruplexes and IGF-1. TMPyP4 tosylate (TMP 1363) is a telomerase inhibitor with antitumor effects in osteosarcoma cell lines.

HY-128845

PROTAC CRBN Degrader-1	PROTAC	Cancer
PROTAC CRBN Degrader-1 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group. PROTAC CRBN Degrader-1 is an cereblon (CRBN) degrader.

HY-12650

Mirogabalin DS5565	Calcium Channel	Neurological Disease
Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium channel complexes in the CNS.

HY-N6777

Penicillic acid	Caspase Bacterial Apoptosis Antibiotic	Cancer Infection
Penicillic acid is a polyketide mycotoxin produced by several species of Aspergillus and Penicillium, which exhibits cytotoxicity in rat alveolar macrophages (AM) in vitro. Penicillic acid inhibits Fas ligand-induced apoptosis by blocking self-processing of caspase-8.

HY-111871

SNIPER(ABL)-033	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 0.3 μM.

HY-136006

(S,R,S)-AHPC-C6-NH2 dihydrochloride VH032-C6-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 dihydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.

HY-130987

Lenalidomide-C9-aldehyde	E3 Ligase Ligand-Linker Conjugate	Cancer
Lenalidomide-C9-aldehyde is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-C9-aldehyde can be used in the synthesis of a series of PROTACs, such as INY-03-041 (HY-133120). INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader. INY-03-041 inhibits Akt1, Akt2 and Akt3 with IC₅₀s of 2.0 nM, 6.8 nM and 3.5 nM, respectively.

HY-133487B

(S,R,S)-AHPC-C8-NH2 VH032-C8-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.

HY-130814

Thalidomide-NH-C4-NH2 TFA	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612). PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader.

HY-136006A

(S,R,S)-AHPC-C6-NH2 hydrochloride VH032-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.

HY-133487

(S,R,S)-AHPC-C8-NH2 dihydrochloride VH032-C8-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.

HY-130711A

(S,R,S)-AHPC-C3-NH2 TFA VH032-C3-NH2 TFA	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.

HY-130711

(S,R,S)-AHPC-C3-NH2 VH032-C3-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.

HY-133487A

(S,R,S)-AHPC-C8-NH2 hydrochloride VH032-C8-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C8-NH2 hydrochloride (VH032-C8-NH2 hydrochloride) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 hydrochloride is XF038-164A, example 8, extracted from patent WO2019173516A1.

HY-44103

Desmethyl-QCA276 PROTAC BRD4-binding moiety 4	Ligand for Target Protein for PROTAC	Cancer
Desmethyl-QCA276, the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC₅₀ of 10 nM, and with a K_i of 2.3 nM.

HY-22024

5-Hydroxyflavone
Others Cancer

5-Hydroxyflavone, a flavonoid ligand, shows no cytotoxic activity against MCF-7, FaDU, MDA-MB-435S, U87, RPE-1, and HEK293 cells.

HY-128838

PROTAC ERRα Degrader-1	PROTAC Estrogen Receptor/ERR	Cancer
PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an PROTAC estrogen-related receptor alpha (ERRa) degrader.

HY-P1166

UFP-803	Urotensin Receptor	Cardiovascular Disease
UFP-803 is a potent urotensin-II receptor (UT) ligand. UFP-803 has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.

HY-101310

SYM 2081	iGluR	Neurological Disease
SYM 2081 is a high-affinity ligand and potent, selective agonist of kainate receptors, inhibits [³H]-kainate binding with an IC₅₀ of 35 nM, almost 3000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively.

HY-N0499

Cyanidin Chloride IdB 1027	Others	Cancer
Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression.

HY-B0573

Propranolol hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Propranolol hydrochloride is a nonselective *β-adrenergic* receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with K_i values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [³H]-DHA binding to rat brain membrane preparation with an IC₅₀** of 12 nM. Propranolol hydrochloride is used to control hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.

HY-B0573B

Propranolol	Adrenergic Receptor	Neurological Disease Cardiovascular Disease Endocrinology
Propranolol is a nonselective *β-adrenergic* receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with K_i values of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [³H]-DHA binding to rat brain membrane preparation with an IC₅₀** of 12 nM. Propranolol is used to control hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.

HY-120179

LP-922761	Others	Neurological Disease
LP-922761 is a potent, selective and orally active adapter protein-2 associated kinase 1 (AAK1) inhibitor with an in vitro IC₅₀ of 4.8 nM and a cellular IC₅₀ of 7.6 nM. LP-922761 also inhibits BMP-2-inducible protein kinase (BIKE) with an IC₅₀ of 24 nM. LP-922761 exhibits no significant activity at cyclin G-associated kinase (GAK), opioid, adrenergic α2 or GABAa receptors.

HY-B2087S

Glycerol phenylbutyrate-D15 HPN-100-D15	Sigma Receptor	Cardiovascular Disease
Glycerol phenylbutyrate-D15 is a deuterium labeled Glycerol phenylbutyrate. Glycerol phenylbutyrate is a sigma-2 (σ2) receptor ligand, with a pK_i of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.

HY-135250B

Thalidomide-O-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-C6-NH2 hydrochloride is a synthesized *E3 ligase ligand-linker conjugate* used in the PROTAC dTAG-13, a degrader of FKBP12^F36V and BET.

HY-114872

SLF	Ligand for Target Protein for PROTAC FKBP	Cancer
SLF is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for FKBP51 and an IC₅₀ of 0.22 μM for FKBP12. SLF can be used in the synthesis of PROTAC.

HY-10232

THIP Gaboxadol	GABA Receptor	Neurological Disease
THIP (Gaboxadol) is a selective δ-aminobutyric acid type A receptor (δ-GABAAR) agonist, functionally selective GABAAR ligand, exhibits agonism at α4β1δ, α4β3δ and weak antagonism at αβγ and α4β2δ GABAARs.

HY-131232

Desmorpholinyl Navitoclax-NH-Me Desmorpholinyl ABT-263-NH-Me	Bcl-2 Family Ligand for Target Protein for PROTAC	Cancer
Desmorpholinyl Navitoclax-NH-Me is a Bcl-xL inhibitor. Desmorpholinyl Navitoclax-NH-Me and a CRBN ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC BCL-XL degrader XZ739 (HY-133557).

HY-108372

Boc-C5-O-C5-O-C6-Cl PROTAC Linker 2	PROTAC Linker	Cancer
Boc-C5-O-C5-O-C6-Cl (PROTAC Linker 2) is a PROTAC linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.

HY-B2087S1

Glycerol phenylbutyrate-D5 HPN-100-D5	Sigma Receptor	Cardiovascular Disease
Glycerol phenylbutyrate-D5 is a deuterium labeled Glycerol phenylbutyrate. Glycerol phenylbutyrate is a sigma-2 (σ2) receptor ligand, with a pK_i of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.

HY-135250

Thalidomide-O-C6-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-C6-NH2 is a synthesized *E3 ligase ligand-linker conjugate* used in the PROTAC dTAG-13, a degrader of FKBP12^F36V and BET.

HY-112603

AP5	GPR40	Metabolic Disease
AP5 exhibits potent and selective agonism for the GPR40 receptor with positive allosteric modulation of endogenous ligands (AgoPAM). AP5 demonstrates a rat hIP1 EC₅₀ of 0.49±0.28 nM against the GPR40 receptor.

HY-N2078

Yamogenin Neodiosgenin	LXR	Metabolic Disease
Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes.

HY-124619

GPI-1046	FKBP HIV	Infection Neurological Disease
GPI-1046 is a immunophilin ligand without antibiotic action and attenuates ethanol intake in part through the upregulation of glutamate transporter 1 (GLT1) in PFC and NAc-core. GPI-1046 is an analog of FK506, which is an immunophilin ligand that has been shown neuroprotective effects in neurodegenerative disease models. GPI-1046 readily crosses the blood-brain barrier and promotes the regeneration of dopamine (DA) cells in the CNS in association with functional recovery in rodent models. GPI-1046 improves HIV-associated injury of peripheral nerves.

HY-130816

(S,R,S)-AHPC-O-Ph-PEG1-NH2 VH032-O-Ph-PEG1-NH2	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614). PROTAC EED degrader-1 is a PROTAC targeting EED with a pK_D of 9.02.

HY-130709

PROTAC CDK2/9 Degrader-1	PROTAC CDK	Cancer
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC₅₀=62 nM) and CDK9 (DC₅₀=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC₅₀=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with CRBN ligand.

HY-17537

APY29	IRE1	Cancer
APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC₅₀ of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain.

HY-135034

UMB68 sodium	Others	Neurological Disease
UMB68 sodium is a selective GHB receptor ligand. UMB68 sodium displaces [³H]NCS-382 with an IC₅₀ of 38 nM in rat cerebrocortical membranes. UMB68 sodium has no significant affinity at GABAB receptors, cannot be metabolized to GABA-active compounds.

HY-128605

PD-1-IN-22
PD-1/PD-L1 Cancer

PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC₅₀ of 92.3 nM.

HY-135250A

Thalidomide-O-C6-NH2 TFA	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-O-C6-NH2 TFA is a synthesized *E3 ligase ligand-linker conjugate* used in the PROTAC dTAG-13, a degrader of FKBP12^F36V and BET.

HY-129363

AP1867-3-(aminoethoxy)	Ligand for Target Protein for PROTAC FKBP	Cancer
AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader.

HY-P1166A

UFP-803 TFA	Urotensin Receptor	Cardiovascular Disease
UFP-803 TFA is a potent urotensin-II receptor (UT) ligand. UFP-803 TFA has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.

HY-120210

XY018	ROR	Cancer Inflammation/Immunology
XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).

HY-B2078A

Eprazinone dihydrochloride	Neurokinin Receptor	Inflammation/Immunology
Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a neurokinin 1 receptor (NK1R) ligand. Eprazinone dihydrochloride has the potential for chronic bronchitis treatment that improved pulmonary function and arterial partial pressure of oxygen.

HY-44432

Navitoclax-piperazine ABT-263-piperazine	Bcl-2 Family Ligand for Target Protein for PROTAC	Cancer
Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604).

HY-136163

(S,R,S)-AHPC-C2-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C2-NH2 dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-OH can be used in the synthesis of a series of PROTACs.

HY-128842

PROTAC MDM2 Degrader-3	PROTAC MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-3 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-128843

PROTAC MDM2 Degrader-4	PROTAC MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-4 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-108635

C16-PAF PAF (C16)	Endogenous Metabolite
C16-PAF is an endogenous platelet-activating factor (PAF) and ligand for PAF receptors. C16-PAF is produced by inflammatory cells and a potent chemoattractant for polymorphonuclear neutrophils. C16-PAF induces increased vascular permeability.

HY-128840

PROTAC MDM2 Degrader-1	PROTAC MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-1 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-128841

PROTAC MDM2 Degrader-2	PROTAC MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-2 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-122872

MKK7-COV-9	p38 MAPK	Cancer
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC₅₀ of 4.98 μM.

HY-B0573S

Propranolol D7 hydrochloride	Adrenergic Receptor	Endocrinology Neurological Disease Cardiovascular Disease
Propranolol D7 hydrochloride is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective *β-adrenergic* receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with K_i values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [³H]-DHA binding to rat brain membrane preparation with an IC₅₀** of 12 nM. Propranolol hydrochloride is used to control hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.

HY-130619

Boc-C1-PEG3-C4-OBn	PROTAC Linker	Cancer
Boc-C1-PEG3-C4-OBn (PROTAC Linker 15) is a PROTAC linker, which refers to the PEG composition. Boc-C1-PEG3-C4-OBn can be used in the synthesis of a series of PROTACs, such as PROTAC SGK3 degrader-1 (HY-125878). PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-133234

BMVC-8C3O
G-quadruplex Others

BMVC-8C3O is a DNA G-quadruplexe (G4) ligand which can induce topological conversion of non-parallel to parallel forms in human telomeric DNA G4s.

HY-P9920

Ramucirumab	VEGFR	Cancer
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.

HY-14422

SR1078	ROR	Cancer
SR1078 is a selective agonist of retinoic acid receptor-related orphan receptor α/γ (RORα/RORγ). SR1078 directly binds to the ligand binding domain of RORα and RORγ and increases the transcriptional activity of these receptors, leading to stimulation of RORα/γ target gene transcription.

HY-W040270

Amino-PEG10-amine	PROTAC Linker	Cancer
Amino-PEG10-amine, a PEG-based PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.

HY-13956S

Pioglitazone D4 U 72107 D4	PPAR Ferroptosis	Cancer Metabolic Disease
Pioglitazone D4 (U 72107 D4) is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-110318

VUF11207 fumarate	CXCR	Cancer
VUF11207 fumarate (Compound 29) is a CXCR7 agonist and a high-potency CXCR7 (pK_i of 8.1) ligand that induces recruitment of β-arrestin2 (pEC₅₀ of 8.8) and subsequent internalization (pEC₅₀ of 7.9) of CXCR7.

HY-P1297

CRF(6-33)(human)	CRFR	Neurological Disease
CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect.

HY-107443

I-BET762 carboxylic acid Molibresib carboxylic acid; GSK525762A carboxylic acid; PROTAC BRD4-binding moiety 2	Ligand for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a BRD4 inhibitor with a pIC₅₀ of 5.1.

HY-P1219

Jingzhaotoxin-III	Sodium Channel	Neurological Disease
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype^{[1]^{^{[2]^.}}}

HY-N0368

Linalool	iGluR Apoptosis Endogenous Metabolite	Cancer Cardiovascular Disease
Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity.Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome.

HY-120879

PF2562	Dopamine Receptor	Neurological Disease
PF2562 (Example 6), a dopamine D1 ligand, ascts as a dopamine D1 agonist or partial agonist. PF2562 binds to human D1 receptor with a K_i of 113 nM. PF2562 exhibits activity against human D1 cAMP with an EC₅₀ of 568 nM in HTRF assay.

HY-136160

Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride can be used to design the PROTACs.

HY-130411

Amino-PEG11-amine	PROTAC Linker	Cancer
Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.

HY-130835

FKBP12 PROTAC RC32 RC32	PROTAC FKBP	Cancer
FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an E3 ubiquitin ligase (Pomalidomide; HY-10984).

HY-N0443

N-Methylcytisine Caulophylline	nAChR	Inflammation/Immunology
N-Methylcytisine (Caulophylline), a tricyclic quinolizidine alkaloid, exerts hypoglycaemic, analgesic and anti-inflammatory activities. N-methylcytisine is a selective ligand of nicotinic receptors of acetylcholine in the central nervous system and has a high affinity (K_d = 50 nM) to nicotinic acetylcholine receptors (nAChR) from squid optical ganglia.

HY-15615A

TIC10 ONC-201	TNF Receptor Apoptosis	Cancer
TIC10 is a potent, orally active, and stable tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducer which acts by inhibiting Akt and ERK, consequently activating Foxo3a and significantly inducing cell surface TRAIL. TIC10 can cross the blood-brain barrier.

HY-P1846

Jagged-1 (188-204)	Notch	Cancer
Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.

HY-P1219A

Jingzhaotoxin-III TFA	Sodium Channel	Neurological Disease
Jingzhaotoxin-III TFA is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III TFA can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype^{[1]^{^{[2]^.}}}

HY-P1740

RGD peptide (GRGDNP)	Integrin Apoptosis	Inflammation/Immunology
RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. RGD peptide (GRGDNP) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.

HY-130842

β-Naphthoflavone-CH2-Br β-NF-CH2-Br	Ligand for E3 Ligase	Cancer
β-Naphthoflavone-CH2-Br (β-NF-CH2-Br) is an arylhydrocarbon receptor (AhR) ligand. β-Naphthoflavone-CH2-Br can be used to synthesize the PROTAC β-NF-JQ1(HY-130256).

HY-136281

DuP 734	Sigma Receptor	Neurological Disease
DuP 734 is a sigma receptor antagonist. DuP 734 is a selective and potent sigma and 5-HT2 receptor ligand with weak affinity for D2 receptors. DuP 734 may have antipsychotic activity without the liability of motor side effects typical of neuroleptics.

HY-136008A

VH032-PEG1-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
VH032-PEG1-NH2 hydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VH032-PEG1-NH2 hydrochloride can be used to design PROTACs.

HY-P1846A

Jagged-1 (188-204) (TFA)	Notch	Cancer
Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.

HY-108512

PD 144418	Sigma Receptor	Neurological Disease
PD 144418 is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (K_i values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 devoids of any significant affinity for other receptors, ion channels and enzymes. PD 144418 shows potential antipsychotic activity.

HY-136406

Bongkrekic acid	ATP Synthase	Cancer Infection
Bongkrekic acid is a mitochondrial toxin secreted by the bacteria Pseudomonas cocovenenans. Bongkrekic acid specific ligand for mitochondrial adenine nucleotide translocase (ANT) rather than the electron transport chain. Bongkrekic acid has to cross the mitochondrial inner membrane to produce its inhibitory effect on ADP/ATP transport.

HY-P1297A

CRF(6-33)(human) TFA	CRFR	Neurological Disease
CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect.

HY-111874

SNIPER(ABL)-039	SNIPER Bcr-Abl	Cancer
SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 10 nM. IC₅₀s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively.

HY-43869

Vipivotide tetraxetan Linker PSMA-617 Linker	ADC Linker	Cancer
Vipivotide tetraxetan Linker (PSMA-617 Linker) is a nonclaevable peptide linker for synthesis of Vipivotide tetraxetan (PSMA-617). Vipivotide tetraxetan (PSMA-617) is a ligand used to synthesize ¹⁷⁷Lu-PSMA-617, which is a radioactive molecule for the treatment of prostate cancer.

HY-P1022

Kisspeptin-54(human) Metastin(human)	GNRH Receptor	Cancer Endocrinology
Kisspeptin-54(human) (Metastin(human)) is an endogenous ligand for kisspeptin receptor (KISS1, GPR54). Kisspeptin-54(human) binds to rat and human GPR54 receptors with K_i values of 1.81 nM and 1.45 nM, respectively. Kisspeptin-54(human) hinders tumor metastasis and stimulates gonadotropin secretion.

HY-P1306

Obestatin(rat)	GHSR	Inflammation/Immunology Cardiovascular Disease
Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) has anti-inflammatory, anti-myocardial infarction and antioxidant activities.

HY-P1740A

RGD peptide (GRGDNP) (TFA)	Integrin Apoptosis	Inflammation/Immunology Cancer
RGD peptide (GRGDNP) (TFA) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.

HY-130683

Lenalidomide-propargyl-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Lenalidomide-propargyl-C2-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Lenalidomide-propargyl-C2-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).

HY-130638

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc VH032-O-Ph-PEG1-NH-Boc	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is a synthesized *E3 ligase ligand-linker conjugate* which is used for the EED-targeted PROTAC.

HY-111848

PROTAC AR Degrader-4	SNIPER PROTAC Androgen Receptor	Cancer
PROTAC AR Degrader-4 comprises a cIAP1 ligand binding group, a linker and an androgen receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).

HY-14541

Olanzapine LY170053	5-HT Receptor Dopamine Receptor mAChR Adrenergic Receptor Autophagy Mitophagy Apoptosis	Neurological Disease Cancer
Olanzapine (LY170053) is a selective monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (K_i=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (K_i=11 to 31 nM), muscarinic M1-5 (K_i=1.9-25 nM), and adrenergic α1 receptor (K_i=19 nM). Olanzapine is an atypical antipsychotic.

HY-111905

BRD7-IN-1	Epigenetic Reader Domain	Cancer
BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC₅₀s of 4.5 and 1.8 nM, respectively).

HY-P1525

Melanin Concentrating Hormone, salmon MCH (salmon)	MCHR1 (GPR24)	Metabolic Disease Neurological Disease Cardiovascular Disease Endocrinology
Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.

HY-118482

Sauristolactam Saurolactam	Others	Neurological Disease
Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells. Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation.

HY-123921

Gefitinib-based PROTAC 3	PROTAC EGFR	Cancer
Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC₅₀s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.

HY-108512A

PD 144418 oxalate	Sigma Receptor	Neurological Disease
PD 144418 oxalate is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (K_i values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 oxalate devoids of any significant affinity for other receptors, ion channels and enzymes. PD 144418 oxalate shows potential antipsychotic activity.

HY-128838A

(rel)-PROTAC ERRα Degrader-1	Others	Others
(rel)-PROTAC ERRα Degrader-1 is a relative configuration of PROTAC ERRα Degrader-1. PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an estrogen-related receptor alpha (ERRa) degrader.

HY-108006

Mirogabalin besylate DS 5565 besylate	Calcium Channel	Neurological Disease
Mirogabalin besylate is a selective and orally available ligand for the α2δ subunit of voltage-gated calcium channels, with K_ds of 13.5 nM, 22.7 nM, 27 nM, and 47.6 nM for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2, respectively.

HY-111905A

BRD7-IN-1 free base	Epigenetic Reader Domain	Cancer
BRD7-IN-1 free base, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC₅₀s of 4.5 and 1.8 nM, respectively).

HY-130256

β-NF-JQ1	PROTAC Epigenetic Reader Domain	Cancer
β-NF-JQ1 is a PROTAC that recruits AhR E3 ligase to target proteins. β-NF-JQ1 is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand, induces the interaction of AhR and BRD proteins, and displays effective anticancer activity that correlated with protein knockdown activity.

HY-P1039

R18 PHCVPRDLSWLDLEANMCLP	Others	Cancer
R18 is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1.

HY-107452

SLF-amido-C2-COOH PROTAC FKBP12-binding moiety 1	Ligand for Target Protein for PROTAC FKBP	Cancer
SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for FKBP (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs.

HY-114407

TD-428	PROTAC Epigenetic Reader Domain	Cancer
TD-428 is a highly specific BRD4 degrader with a DC₅₀ of 0.32 nM. TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation.

HY-P1306A

Obestatin(rat) TFA	GHSR	Inflammation/Immunology Cardiovascular Disease
Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) TFA has anti-inflammatory, anti-myocardial infarction and antioxidant activities.

HY-112210

Shield-1	FKBP	Others
Shield-1 is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize the entire fusion protein.

HY-107453

SirReal1-O-propargyl PROTAC Sirt2-binding moiety 1	Ligand for Target Protein for PROTAC	Cancer
SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC₅₀ of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2.

HY-10122

Silodosin KAD 3213; KMD 3213	Adrenergic Receptor	Cancer Endocrinology
Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active *α1A-adrenergic* receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (K_i=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i** values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH.

HY-112461A

NF449 octasodium	P2X Receptor	Cardiovascular Disease
NF449 octasodium is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 octasodium is a G_sα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s.

HY-114169

WRG-28	Discoidin Domain Receptor	Cancer
WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor with an IC₅₀ of 230 nM. WRG-28 uniquely inhibits receptor-ligand interactions via allosteric modulation of the receptor. WRG-28 inhibits tumor invasion and migration, as well as tumor-supporting roles of the stroma, and inhibits metastatic breast tumor cell colonization in the lungs by targeting DDR2.

HY-P1525A

Melanin Concentrating Hormone, salmon TFA MCH (salmon) (TFA)	MCHR1 (GPR24)	Metabolic Disease Neurological Disease Cardiovascular Disease Endocrinology
Melanin Concentrating Hormone, salmon TFA (MCH (salmon) TFA) is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.

HY-P1022A

Kisspeptin-54(human) TFA Metastin(human) TFA	GNRH Receptor	Cancer Endocrinology
Kisspeptin-54(human) TFA (Metastin(human) TFA) is an endogenous ligand for kisspeptin receptor (KISS1, GPR54). Kisspeptin-54(human) TFA binds to rat and human GPR54 receptors with K_i values of 1.81 nM and 1.45 nM, respectively. Kisspeptin-54(human) TFA hinders tumor metastasis and stimulates gonadotropin secretion.

HY-130682

Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugate	Cancer
Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase and a linker. Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).

HY-135881

OMDM-5	TRP Channel Endogenous Metabolite	Neurological Disease
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent vanilloid receptor type 1 (VR1, TRPV1) agonist, with an EC₅₀ of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM).

HY-122054

BPK-29	Others	Cancer
BPK-29 is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein (such RBM45 and SNW1) interactions by covalently modifying C274. BPK-29 impairs the anchorage-independent growth of KEAP1-mutant cancer cells.

HY-122054A

BPK-29 hydrochloride	Others	Cancer
BPK-29 hydrochloride is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein (such RBM45 and SNW1) interactions by covalently modifying C274. BPK-29 hydrochloride impairs the anchorage-independent growth of KEAP1-mutant cancer cells.

HY-133139

Lenalidomide-PEG1-azide	E3 Ligase Ligand-Linker Conjugate	Cancer
Lenalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-PEG1-azide can be used to design a PROTAC BRD4 Degrader-2 (HY-133136).

HY-130654

(S,R,S)-AHPC-C2-PEG4-N3 VH032-C2-PEG4-N3	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized *E3 ligase ligand-linker conjugate* that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC₅₀) of 82 nM.

HY-130642

(S,R,S)-AHPC-Me-C10-Br	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-Me-C10-Br is a synthesized *E3 ligase ligand-linker conjugate*. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901.

HY-16781

Grapiprant CJ-023423; RQ-00000007; AAT-007	Prostaglandin Receptor	Metabolic Disease Endocrinology
Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E₂ (PGE₂). Grapiprant displaces [³H]-PGE₂ (1 nM) binding to dog recombinant EP4 receptor with IC₅₀ value of 35 nM and K_i value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment^[3].

HY-W020790

Sialyl-Lewis X sLeX	Others	Inflammation/Immunology
Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity *ligand* for selectins (E-, P-, and L-selectin). Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability to inhibits CD62-mediated neutrophil recruitment to sites of inflammation.

HY-129603

SI-109	STAT Ligand for Target Protein for PROTAC	Cancer
SI-109 is a potent STAT3 SH2 domain inhibitor (K_i=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC₅₀=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36.

HY-130713

Thalidomide-C2-amido-C2-COOH	E3 Ligase Ligand-Linker Conjugate	Cancer
Thalidomide-C2-amido-C2-COOH incorporates a CRBN ligand for the E3 ubiquitin ligase, and a linker. Thalidomide-C2-amido-C2-COOH can be used to design PROTAC CDK2/9 Degrader-1 (HY-130709).

HY-107676

SIB-1553A	nAChR	Neurological Disease
SIB-1553A is an orally bioavailable nicotinic acetylcholine receptors (nAChRs) agonist, with selectivity for β4 subunit-containing nAChRs. SIB-1553A is also a selective neuronal nAChR ligand. SIB-1553A is a cognitive enhancer, and has therapeutic potential for the symptomatic treatment of Alzheimer’s disease and other cognitive disorders.

HY-133138

Pomalidomide-PEG1-azide	E3 Ligase Ligand-Linker Conjugate	Cancer
Pomalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-PEG1-azide can be used to design a PROTAC BRD4 Degrader-1 (HY-133131).

HY-131188

PROTAC Bcl-xL degrader-1	PROTAC Bcl-2 Family	Cancer
PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL ligand binding group, a linker and an IAP E3 ligases binding group. PROTAC Bcl-xL degrader-1 is a potent Bcl-xL degrader, and shows toxicity for human platelets and MyLa 1929 cells with IC₅₀ values of 62 nM and 8.5 μM, respectively.

HY-14541S

Olanzapine D3 LY170053 D3	5-HT Receptor Dopamine Receptor mAChR Adrenergic Receptor Autophagy Mitophagy Apoptosis	Cancer Neurological Disease
Olanzapine D3 (LY170053 D3) is the deuterium labeled Olanzapine. Olanzapine is a selective monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (K_i=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (K_i=11 to 31 nM), muscarinic M1-5 (K_i=1.9-25 nM), and adrenergic α1 receptors (K_i=19 nM). Olanzapine is an atypical antipsychotic.

HY-N2025

Oroxin A	PARP Glucosidase	Metabolic Disease
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE), activates peroxisome proliferator-activated receptor γ (PPARγ) by docking into the PPARγ protein ligand-binding domain. Oroxin A exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.

HY-15523A

Braco-19 trihydrochloride	DNA/RNA Synthesis CMV	Cancer Infection
Braco-19 trihydrochloride is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor.

HY-13912

IWP-2	Wnt Casein Kinase	Cancer
IWP-2 is an inhibitor of Wnt processing and secretion with an IC₅₀ of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. IWP-2 is also an ATP-competitive CK1δ inhibitor with an IC₅₀ of 40 nM for the gatekeeper mutant ^M82FCK1δ.

HY-122607

DPA-714	Others	Cancer Inflammation/Immunology
DPA-714 is a high affinity translocator protein (TSPO) ligand (K_i=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. [18F]DPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model.

HY-15523

Braco-19	CMV DNA/RNA Synthesis	Cancer
Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor.

HY-110358

QAQ dichloride	Sodium Channel	Inflammation/Immunology
QAQ dichloride, a photoswitchable voltage-gated Na_v and K_v channels blocker, blocks channels in its trans form (of the azobenzene photoswitch), but not in its cis form. QAQ dichloride is membrane-impermeant and only infiltrates pain-sensing neurons that express endogenous import channels. QAQ dichloride acts as a light-sensitive analgesic and can be used for studying of signaling mechanisms in acute and chronic pain.

HY-111846

PROTAC ERα Degrader-2	SNIPER PROTAC Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-2 comprises a cIAP1 ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).

HY-10019

Varenicline CP 526555	nAChR	Neurological Disease
Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment.

HY-111546

BI-3663	PROTAC FAK	Cancer
BI-3663 is a highly selective PTK2/FAK PROTAC, with cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC₅₀ of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker. Anti-cancer activity.

HY-110287

Apcin	APC	Cancer
Apcin, a ligand of Cdc20, is a potent and competitive anaphase-promoting complex/cyclosome (APC/C(Cdc20)) E3 ligase activity inhibitor. Apcin competitively inhibits APC/C-dependent ubiquitylation by binding to Cdc20 and preventing substrate recognition. Apcin occupes the D-box-binding pocket on the side face of the WD40-domain and can prolong mitosis.

HY-P2036

FSL-1	Toll-like Receptor (TLR) Antibiotic	Infection
FSL-1 is a TLR2/6 agonist (also a putative TLR10 ligand). FSL-1 activates NF-κB. FSL-1 induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. FSL-1 synergizes with IFNγ to induce CXCL10 release from melanoma cells.

HY-100277

Mifobate SR-202	PPAR	Metabolic Disease
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC₅₀=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects.

HY-10046

Plerixafor AMD 3100; JM3100; SID791	CXCR HIV Virus Protease	Cancer Infection Endocrinology Inflammation/Immunology
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM.

HY-12397

ZK159222	VD/VDR	Endocrinology
ZK159222, a 25-carboxylic ester analogue of 1α,25-(OH)2D3, is a potent 1α,25-(OH)2D3 receptor (VDR) antagonist. The mechanism of ZK159222 antagonistic action is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. ZK159222 has a partial agonistic character.

HY-12028

PD98059	MEK Aryl Hydrocarbon Receptor Autophagy	Cancer
PD98059 is a potent and selective MEK inhibitor with an IC₅₀ of 5 µM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC₅₀ of 2-7 µM) and MEK2 (IC₅₀ of 50 µM) by upstream kinases. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC₅₀ of 4 μM) and AHR transformation (IC₅₀ of 1 μM). PD98059 also inhibits autophagy.

HY-N2453

Convallatoxin	PPAR NF-κB P-glycoprotein	Cancer Inflammation/Immunology
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties.

HY-117727

Leriglitazone Hydroxypioglitazone	PPAR	Metabolic Disease
Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with K_i of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC₅₀ of 680 nM.

HY-P1204

[Ala17]-MCH	MCHR1 (GPR24)	Metabolic Disease
[Ala17]-MCH, a MCH analogue (HY-P1525A), is a selective ligand for MCHR₁ (K_i=0.16 nM) over MCHR₂ (K_i=34 nM). [Eu³⁺ chelate-labeled [Ala17]-MCH shows high affnity for MCHR₁ (K_d=0.37 nM) while has little demonstrable binding affnity for MCHR₂.

HY-P1204A

[Ala17]-MCH TFA	MCHR1 (GPR24)	Metabolic Disease
[Ala17]-MCH TFA, a MCH analogue (HY-P1525A), is a selective ligand for MCHR₁ (K_i=0.16 nM) over MCHR₂ (K_i=34 nM). [Eu³⁺ chelate-labeled [Ala17]-MCH shows high affnity for MCHR₁ (K_d=0.37 nM) while has little demonstrable binding affnity for MCHR₂.

HY-100848

TX1-85-1	EGFR	Cancer
TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC₅₀ of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.

HY-125877

PROTAC Mcl1 degrader-1	PROTAC Bcl-2 Family	Cancer
PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC), is a potently and selectively Mcl-1 inhibitor with an IC₅₀ of 0.78 μM. PROTAC Mcl1 degrader-1 induces the ubiquitination and proteasomal degradation of Mcl-1 by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1 inhibitor S1-6 with μM-range affinity.

HY-125876

PROTAC Bcl2 degrader-1	PROTAC Bcl-2 Family	Cancer
PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC, which potently and selectively induces the degradation of Bcl-2 (IC₅₀, 4.94 μM; DC₅₀, 3.0 μM) and Mcl-1 (IC₅₀, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1.

HY-P2036A

FSL-1 TFA	Toll-like Receptor (TLR) Antibiotic	Infection
FSL-1 TFA is a TLR2/6 agonist (also a putative TLR10 ligand). FSL-1 TFA activates NF-κB. FSL-1 TFA induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. FSL-1 TFA synergizes with IFNγ to induce CXCL10 release from melanoma cells.

HY-126252

A-9758	ROR Interleukin Related	Inflammation/Immunology
A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC₅₀=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation.

HY-112495

VH032-PEG5-C6-Cl HaloPROTAC 2	PROTAC	Cancer
VH032-PEG5-C6-Cl (HaloPROTAC 2) is a small molecule HaloPROTAC that incorporates the VH032 based VHL ligand and 5-unit PEG linker. VH032-PEG5-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-13001

Quizartinib AC220	FLT3 Ligand for Target Protein for PROTAC Apoptosis Autophagy	Cancer
Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC₅₀s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis.

HY-129610

KB02-SLF	PROTAC FKBP	Cancer
KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF.

HY-130815

MAK683-CH2CH2COOH	Histone Methyltransferase Ligand for Target Protein for PROTAC	Cancer
MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615).

HY-130983

N-piperidine Ibrutinib hydrochloride	Btk Ligand for Target Protein for PROTAC	Cancer
N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC₅₀s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620 (HY-133137). SJF620 is a potent PROTAC BTK degrader with a DC₅₀ of 7.9 nM.

HY-123919

TL13-112	PROTAC ALK	Cancer
TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC₅₀ value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC₅₀ values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib (HY-15656) and the cereblon ligand of Pomalidomide (HY-10984).

HY-116624

MAZ51	VEGFR Apoptosis	Cancer
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity.

HY-110155

LM11A-31 dihydrochloride	Others	Neurological Disease
LM11A-31 dihydrochloride, a non-peptide p75^NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. M11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.

HY-110155A

(Rac)-LM11A-31 dihydrochloride	Others	Neurological Disease
(Rac)-LM11A-31 dihydrochloride is an isomer of LM11A-31 dihydrochloride. LM11A-31 dihydrochloride, a non-peptide p75^NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist.

HY-P0172A

ATI-2341 TFA	CXCR	Cancer Inflammation/Immunology Endocrinology
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).

HY-136242

UT-34	Androgen Receptor	Cancer Endocrinology
UT-34 is a potent, selective and orally active second-generation pan-androgen receptor (AR) antagonist and degrader with IC₅₀s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively. UT-34 binds to ligand-binding domain (LBD) and function-1 (AF-1) domains and requires ubiquitin proteasome pathway to degrade the AR. UT-34 has anti-prostate cancer efficacy.

HY-122582

TL13-12	PROTAC ALK	Cancer
TL13-12 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC₅₀ value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC₅₀ values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the cereblon ligand of Pomalidomide (HY-10984).

HY-P0172

ATI-2341	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).

HY-128359

ACBI1	PROTAC Epigenetic Reader Domain Apoptosis	Cancer
ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4, also degrades the polybromo-associated BAF (PBAF) complex member PBRM1, with DC₅₀s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 can induce anti-proliferative effects and apoptosis.

HY-117163

FzM1.8	Wnt β-catenin	Cancer
FzM1.8 derives from FzM1, is an allosteric agonist of FZD4 with pEC₅₀ of 6.4. FzM1.8 binds to FZD4 and activates the WNT/β-catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 binding stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K.

HY-103636

PROTAC Sirt2 Degrader-1	Sirtuin PROTAC	Cancer
PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC₅₀ of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC₅₀s>100 μM).

HY-119109

Laminaran	Others	Cancer
Laminaran is a neutral water-soluble β-1-3-glucan and a typical ligand for Dectin-1 isolated from the brown alga D. dichotoma, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

HY-130422

Tos-PEG4-t-butyl ester Tos-PEG4-Boc	PROTAC Linker	Cancer
Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) is a PROTAC linker, which refers to the PEG composition. Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) can be used in the synthesis of a series of PROTACs, such as BI-3663 (HY-111546). BI-3663 is a highly selective PTK2/FAK PROTAC, with cereblon ligands to hijack E3 ligases for PTK2 degradation, and inhibits PTK2 with an IC₅₀ of 18 nM.

HY-129917

KB02-JQ1	PROTAC Epigenetic Reader Domain	Cancer
KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1.

HY-130612

PROTAC BRD2/BRD4 degrader-1	Epigenetic Reader Domain PROTAC	Cancer
PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein BRD4 and BRD2 degrader. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3. It effectively inhibits solid tumors with low cytotoxic effect. PROTAC BRD2/BRD4 degrader-1 is composed of the BET inhibitor, a linker, and the ligand thalidomide for cereblon (CRBN)/cullin 4A.

HY-129602

SD-36	PROTAC STAT Apoptosis	Cancer
SD-36 is a potent and efficacious PROTAC STAT3 degrader (K_d=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC₅₀=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of CRBN ligand Lenalidomide for E3 ubiquitin ligase.

HY-103241

Ro 90-7501	Amyloid-β ATM/ATR Phosphatase Apoptosis	Cancer Neurological Disease
Ro 90-7501 is an amyloid β₄₂ (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response. Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner. Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells.

HY-120874

PF-06372865	GABA Receptor	Neurological Disease
PF-06372865 is an orally active, α2/α3/α5 subtype-selective GABA_A positive allosteric modulator (PAM). PF-06372865 is a high affinity ligand at GABA_A receptors containing α1/α2/α3/α5 subunits (K_is of 2.9 nM, 21 nM, 134 nM for α2, α1 PAM, α2 PAM, respectively), with low affinity for α4/α6 subunits. PF-06372865 has the potential for epilepsy.

HY-120944

BAY-7598	MMP	Inflammation/Immunology
BAY-7598 is a potent, orally bioavailable, and selective MMP12 inhibitor probe with IC₅₀s of 0.085, 0.67 and 1.1 nM for human MMP12, murine MMP12, and rat MMP12, respectively.

HY-P1320A

[Nphe1]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent.

HY-131187

BMS-1166-N-piperidine-COOH	Ligand for Target Protein for PROTAC	Cancer
BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1. BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.

HY-P1320

[Nphe1]Nociceptin(1-13)NH2	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent.

Cat. No.	Product Name

HY-L0055V

Discovery Diversity Set 50

50,240 compounds

Discovery Diversity Sets (DDS) are high-quality compound libraries focused on novel chemotypes and non-trivial structures. Discovery Diversity Set 50 compose of 50,240 highly diverse compounds produced only within last three years. The two sets do not overlap and deliver a total of 60 thousand compounds. The Discovery Diversity Sets are highly recommended for random screening against new as well as popular targets because they are based on diverse novel scaffolds and latest building blocks. The hits discovered are expected to easily yield lead compounds.

HY-L0083V

Protein Mimetics Library 8,960 compounds

A set of 8,960 compounds targeting alpha-helix and beta-turn domains.

HY-L0054V

Discovery Diversity Set 10

10,560 compounds

Discovery Diversity Sets (DDS) are high-quality compound libraries focused on novel chemotypes and non-trivial structures. Discovery Diversity Set 10 compose of 10,560 highly diverse compounds produced only within last three years. The Discovery Diversity Sets are highly recommended for random screening against new as well as popular targets because they are based on diverse novel scaffolds and latest building blocks. The hits discovered are expected to easily yield lead compounds.

HY-L0080V

Lipoxygenase Library 1,388 compounds

A set of 1,388 Lipoxygenase (LOX) inhibitors designed using docking and 2D similarity search.

HY-L0059V

Allosteric GPCR Library	14,535 compounds
A sub-library of GPCR Library designed for the discovery of novel allosteric ligands. Allosteric GPCRs Library is a utile starting point for the drug discovery in the field of allosteric GPCR modulators.

HY-L0062V

Kinase Hinge Binders Library 22,720 compounds

A unique collection of 22,720 kinase inhibitors targeting ATP binding pocket and designed using ligand-based methods.
HY-L0056V

Hit Locator Library 234,240 compounds

Hit Locator Library (HLL) is a sizable highly diverse screening set of 234,240 novel screening compounds.
HY-L0085V

Tubulin Library 3,454 compounds

A library of 3,454 potential tubulins ligands.

HY-L0088V

Life Chemicals 50K Diversity Library

50,240 compounds

Life Chemicals presents a number of exclusive Pre-Plated Diversity Sets composed of 50,240 novel compounds with optimal physicochemical properties selected from Life Chemicals collection of newly synthesized items by dissimilarity search with an average Tanimoto threshold of 82%. These Diverse Screening Sets are ideal starting points for customers looking for a wide range of dissimilarity to screen against a number of targets from different classes or where little information is available on targeted protein structure.

HY-L0079V

Glycomimetic Library	2,718 compounds
A specially synthesized set of 2,718 compounds able to mimic glycosides and their interaction with proteins. The main emphasis of library design was made on drug-like compounds enriched with H-bond donors (possess at least two H-bond donors) and bearing nature-like Fsp3–rich scaffolds with diverse spatial orientation of H-bond donors and different 3D-shapes.

HY-L0076V

Covalent Screening Library	8,301 compounds
Covalent modifiers have attracted much attention in recent years; over 30% marketed drugs have this mode of action. A set of 8,301 screening compounds bearing “warheads” for covalent target modification has been offered.

HY-L001V

MCE Bioactive Compound Library	10397 compounds
A unique collection of 10397 bioactive compounds including natural products, enzyme inhibitors, receptor ligands, and drugs for high throughput screening (HTS) and high content screening (HCS).

HY-L062

Neurotransmitter Receptor Compound Library

955 compounds

Neurotransmitter (NT) receptors, also known as neuroreceptors, are a broadly diverse group of membrane proteins that bind neurotransmitters for neuronal signaling. There are two major types of neurotransmitter receptors: ionotropic and metabotropic. Ionotropic receptors are ligand-gated ion channels, meaning that the receptor protein includes both a neurotransmitter binding site and an ion channel. The binding of a neurotransmitter molecule (the ligand) to the binding site induces a conformational change in the receptor structure, which opens, or gates, the ion channel. The term “metabotropic receptors” is typically used to refer to transmembrane G-protein-coupled receptors. Metabotropic receptors trigger second messenger-mediated effects within cells after neurotransmitter binding.

In some neurological diseases, the neurotransmitter receptor itself appears to be the target of the disease process. Many neuroactive drugs act by modifying neurotransmitter receptors. A better understanding of neurotransmitter receptor changes in disease may lead to improvements in therapy.

MCE designs a unique collection of 955 compounds targeting a variety of neurotransmitter receptors. MCE Neurotransmitter Receptor Compound Library is a useful tool for neurological diseases drug discovery.

HY-L0064V

Ion Channel Library 36,800 compounds

A unique collection of 36,800 diverse compounds intended to specifically target ion channels has been offered.

HY-L0081V

Molecular Chaperones Library	2,468 compounds
Molecular Chaperones Library comprises 2,468 synthetic compounds targeting most promising and studied targets: Heat shock proteins (Hsp90, Hsp82, Hsp27), chaperone activity of bc1 complex-like and histone-chaperone ASF1a complex (ASF1-histone interaction).

HY-L0060V

Lipid GPCR Library	5,632 compounds
A unique collection of 5,632 small molecules targeting the family of eight endothelial differentiation gene (EDG) receptors (S1P1–5 and LPA1–3) which is suitable for Lipid GPCR screening research.

HY-L059

Pyroptosis Compound Library

499 compounds

Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc.

MCE designs a unique collection of 499 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signal pathway and can be used in the research of pyroptosis signal pathway and related diseases.

HY-L012

Metabolism/Protease Compound Library

2018 compounds

Metabolism is the set of life-sustaining chemical reactions in organisms. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. Acting as catalysts, enzymes are crucial to metabolism - they allow a reaction to proceed more rapidly - and they also allow the regulation of the rate of a metabolic reaction. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. Imbalances in metabolic activities have been found to be critical in a number of pathologies, such as cardiovascular diseases, inflammation, cancer, and neurodegenerative diseases.

MCE designs a unique collection of 2018 Metabolism/Protease-related small molecules that act as a useful tool for drug discovery of metabolism-related diseases.

HY-L047

Endocrinology Compound Library	638 compounds
A unique collection of 638 bioactive compounds related to endocrinology research for high throughput screening (HTS) and high content screening (HCS).

HY-L013

Neuronal Signaling Compound Library

1316 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 1316 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

HY-L0058V

GPCR Library	54,080 compounds
A unique collection of 54,080 small molecules targeting G protein coupled receptors (GPCRs) used in GPCR screening for various research and drug development projects.

HY-L006

GPCR/G Protein Compound Library

1234 compounds

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery.

MCE provide a unique collection of 1234 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

HY-L0051V

HTS Compound Library	2,115,979 compounds
A unique collection contains 2,115,979 diverse screening compounds for the lead identification via high-throughput screening (HTS) and high content screening (HCS).

HY-L001

Bioactive Compound Library

9350 compounds

Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype.

MCE owns a unique collection of 9350 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. These can also be used for signal pathway research, drug discovery and drug repurposing, etc.

HY-L0082V

Nucleoside Mimetics Library 290 compounds

A library of 290 nucleoside mimetics.
HY-L0070V

IDO Targeted Library 1,003 compounds

A unique library of 1,003 diverse compounds targeting IDO.
HY-L0086V

Specs HTS Compounds Library 210,070 compounds

A unique collection contains 210,070 diverse chemical compounds to pharmaceutical and biotechnology scientists for drug discovery.
HY-L0073V

Antiviral Library 4,842 compounds

A unique collection designed for discovery of new Nucleoside-like antivirals
HY-L0067V

Immuno-Oncology Library 52,935 compounds

A unique collection of 52,935 diverse compounds designed for discovery of novel hits in immuno-oncology therapeutic area has been offered.
HY-L0071V

JAK/STAT Compound Library 1,390 compounds

JAK/STAT compound Library was designed to be a universal tool to search potential JAK-STAT pathway modulators.

HY-L016

Protein Tyrosine Kinase Compound Library

528 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 528 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L018

TGF-beta/Smad Compound Library

110 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 110 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

HY-L0065V

CNS Library	55,279 compounds
A unique collection of 55,279 novel small molecules with high CNS MPO (Central Nervous System Multiparameter Optimization) scores. The CNS-active molecules which are able to penetrate blood-brain barrier (BBB) were low polar surface area, low degree of possible hydrogen bond formation and low ClogP values.

Cat. No.	Product Name	Type

HY-D0939

Direct Blue 1 Chicago Sky Blue 6B	Dyes
Direct Blue 1 (Chicago Sky Blue 6B) is a counterstain for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1, structurally related to glutamate, is a potent and competitive VGLUT inhibitor without affecting plasma membrane transporters. Direct Blue 1 is the first small molecule PrP ligand capable of inhibiting Aβ binding.

Cat. No.	Product Name	Type

HY-111413

c(phg-isoDGR-(NMe)k)
Biochemical Assay Reagents

c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC₅₀ of 2.9 nM.
HY-111413A

c(phg-isoDGR-(NMe)k) TFA
Biochemical Assay Reagents

c(phg-isoDGR-(NMe)k) TFA is a selective and potent α5β1-integrin ligand with an IC₅₀ of 2.9 nM.

Cat. No.	Product Name	Target	Research Area

HY-P1840A

*Galanin Receptor Ligand* M35 TFA**	Neuropeptide Y Receptor	Endocrinology Neurological Disease
Galanin Receptor Ligand M35 TFA is a high-affinity ligand and antagonist of galanin receptor (K_d=0.1 nM). Galanin Receptor Ligand M35 TFA exerts a K_i values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.

HY-P1840

*Galanin Receptor Ligand* M35**	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Galanin Receptor Ligand M35 is a high-affinity ligand and antagonist of galanin receptor (K_d=0.1 nM). Galanin Receptor Ligand M35 exerts a K_i values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.

HY-P1887

*p5 Ligand* for Dnak and DnaJ**	HSP	Infection
p5 Ligand for Dnak and DnaJ is a nonapeptide, which corresponds to the main binding site for the 23-residue part of the presequence of mitochondrial aspartate aminotransferase. p5 Ligand for Dnak and DnaJ is a high-affinity ligand for DnaK and DnaJ.

HY-P1868

*α2β1 Integrin Ligand* Peptide**	Integrin	Infection
α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.

HY-P1868A

*α2β1 Integrin Ligand* Peptide TFA**	Integrin	Others
α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.

HY-P1483

Urotensin II, mouse	Urotensin Receptor	Neurological Disease Cardiovascular Disease
Urotensin II, mouse is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse is a potent vasoconstrictor. Urotensin II, mouse plays a physiological role in the central nervous system.

HY-P1483B

Urotensin II, mouse acetate	Urotensin Receptor	Neurological Disease Cardiovascular Disease
Urotensin II, mouse acetate is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse acetate is a potent vasoconstrictor. Urotensin II, mouse acetate plays a physiological role in the central nervous system.

HY-P1483A

Urotensin II, mouse TFA	Urotensin Receptor	Neurological Disease Cardiovascular Disease
Urotensin II, mouse TFA is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse TFA is a potent vasoconstrictor. Urotensin II, mouse TFA plays a physiological role in the central nervous system.

HY-P1318

Ac-RYYRIK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain.

HY-P1318A

Ac-RYYRIK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain.

HY-P0183

Nociceptin
Orphanin FQ
Opioid Receptor Neurological Disease

Nociceptin, a heptadecapeptide, is the endogenous ligand of the nociceptin receptor, acting as a potent anti-analgesic.

HY-P1205A

MCH(human, mouse, rat) TFA	MCHR1 (GPR24)	Neurological Disease
MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC₅₀ values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC₅₀ values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively.

HY-P1380A

Difopein TFA	Apoptosis	Cancer
Difopein (TFA), a specific and competitive inhibitor of 14-3-3 protein (a highly conserved eukaryotic regulatory molecule), blocking the ability of 14-3-3 to bind to target proteins and inhibits 14-3-3/Ligand interactions. Difopein (TFA) leads to induction of apoptosis and enhances the ability of cisplatin to kill cells.

HY-P1944A

Apelin-13 TFA	Peptides	Metabolic Disease Cardiovascular Disease
Apelin-13 is the endogenous ligand of the APJ receptor, activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM.

HY-P2267

LDV
Integrin

LDV, a non-fluorescent derivative of LDV FITC, is a α4β1 integrin (VLA-4) ligand (K_d ~ 12 nM).
HY-P1035

Neuropeptide W-23(human)
NPW-23
Peptides Neurological Disease

Neuropeptide W-23(human), the active form of Neuropeptide W, is an endogenous ligand for NPBW1 and NPBW2.

HY-P2253

H3K27(Me2) (15-34)	Peptides	Cancer
H3K27(Me2) (15-34) is a histone peptide and a repressive mark derived from human histone isotype 3.1. H3K27(Me2) (15-34) is a substrate for methyltransferase/demethylase enzymes. The SET domain of the Polycomb Repressive Complex 2 (PRC2) component EZH2 catalyzes H3K27(Me2) di-methylation.

HY-P1186

Eledoisin Related Peptide Eledoisin-Related Peptide; Eledoisin RP	Neurokinin Receptor	Neurological Disease
Eledoisin Related Peptide is a Substance P analog that excites neurons and triggers behavioral responses. Eledoisin Related Peptide is also a tachykinin receptor ligand.

HY-P0031

Cyclo(RADfK)
Integrin Others

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

HY-P1037

Motilin (26-47), human, porcine	Motilin Receptor	Others
Motilin (26-47), human, porcine is an endogenous motilin receptor ligand with K_i and EC₅₀ of 2.3 nM and 0.3 nM in a Chinese hamster ovary cell line.

HY-P0260

p2Ca
Peptides Inflammation/Immunology

p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.

HY-P1464

Amylin, amide, rat Amylin (rat)	Peptides	Metabolic Disease
Amylin, amide, rat is a potent and high affinity ligand of Amylin receptor AMY1 and AMY3 receptors and variably of AMY2 receptors; binding studies are generally used for the latter receptor.

HY-P2314

HAIYPRH hydrochloride	Peptides	Cancer
HAIYPRH hydrochloride, a targeting ligand, can specially bind to transferrin receptor (TfR). HAIYPRH hydrochloride can mediate the transport of nanocarriers across the blood-brain barrier.

HY-P1922

γ-2-MSH (41-58), amide	Peptides	Endocrinology
γ-2-MSH (41-58), amide is derived from γ-2-MSH. γ-2-MSH is a twelve amino acid peptide that is derived from the N-terminal fragment of proopiomelanocortin (POMC) and contains the His-Phe-Arg-Trp motif common to all melanocortin endogenous agonist ligands.

HY-P1944

Apelin-13	Peptides	Metabolic Disease Cardiovascular Disease
Apelin-13 is the endogenous ligand of the orphan G protein-coupled receptor APJ, activates APJ receptor with an EC₅₀ value of 0.37 nM in CHO cells.

HY-P0272

Peptide T
HIV Infection

Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

HY-P1299A

UFP-101 TFA	Opioid Receptor	Neurological Disease
UFP-101 TFA is a potent, selective, and competitive antagonist of the NOP receptor, with a pK_i of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect.

HY-P1299

UFP-101	Opioid Receptor	Neurological Disease
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pK_i of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect.

HY-P1530

Prolactin Releasing Peptide (12-31), human	Peptides	Neurological Disease
Prolactin Releasing Peptide (12-31), human is a fragment of the prolactin releasing peptide (PrRP). Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin.

HY-P0272A

Peptide T TFA	HIV	Infection
Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

HY-P0224

N-Formyl-Met-Leu-Phe fMLP; N-Formyl-MLF	TNF Receptor	Inflammation/Immunology
N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.

HY-P1447

Exendin-3/4 (64-86)	Peptides	Metabolic Disease
Exendin-3/4 (64-86) is a polypeptide from patent CN 106029087 A. The incretin receptor ligands are derived from multiple skin toxicity Shan exosomes -3 skin of SDGTFTSDLSKQM Di EAVRLFIEWLKNGGPSSGAPPPS.

HY-P2254

H3K27(Me3) (15-34)	Peptides	Cancer
H3K27(Me3) (15-34) is a histone peptide and a repressive mark derived from human histone isotype 3.1. H3K27(Me3) (15-34) is a substrate for methyltransferase/demethylase enzymes. The SET domain of the Polycomb Repressive Complex 2 (PRC2) component EZH2 catalyzes H3K27(Me3) tri-methylation. H3K27(Me3) can be recognized by a chromodomain protein in the canonical Polycomb Repressive Complex 1 (PRC1).

HY-P1520

Prolactin Releasing Peptide (1-31), human	Peptides	Neurological Disease
Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin. Human and rat Prolactin Releasing Peptide (1-31) binds to GPR10 with K_is of 1.03 and 0.33 nM, respectively.

HY-P1915

26Rfa, Hypothalamic Peptide, human	Peptides	Metabolic Disease
26Rfa, Hypothalamic Peptide, human is a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. 26RFa is an orexigenic neuropeptide identified as the endogenous ligand of the orphan G protein-coupled receptor GPR103.

HY-P1166

UFP-803	Urotensin Receptor	Cardiovascular Disease
UFP-803 is a potent urotensin-II receptor (UT) ligand. UFP-803 has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.

HY-P1197

Kisspeptin-10, rat	Peptides	Inflammation/Immunology Cardiovascular Disease
Kisspeptin-10, rat is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, rat is a ligand for the rodent kisspeptin receptor (KISS1, GPR54). Kisspeptin-10 reduces Methotrexate-induced reproductive toxicity as a potential antioxidant compound.

HY-P1166A

UFP-803 TFA	Urotensin Receptor	Cardiovascular Disease
UFP-803 TFA is a potent urotensin-II receptor (UT) ligand. UFP-803 TFA has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.

HY-P1507

Fibrinogen Binding Inhibitor Peptide	Peptides	Cardiovascular Disease
Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.

HY-P9920

Ramucirumab	VEGFR	Cancer
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.

HY-P1297

CRF(6-33)(human)	CRFR	Neurological Disease
CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect.

HY-P1219

Jingzhaotoxin-III	Sodium Channel	Neurological Disease
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype^{[1]^{^{[2]^.}}}

HY-P1366

des-Gln14-Ghrelin	Peptides	Metabolic Disease
des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca²⁺]i in CHO-GHSR62 cells, with an EC₅₀ of 2.4 nM.

HY-P1846

Jagged-1 (188-204)	Notch	Cancer
Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.

HY-P1219A

Jingzhaotoxin-III TFA	Sodium Channel	Neurological Disease
Jingzhaotoxin-III TFA is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III TFA can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype^{[1]^{^{[2]^.}}}

HY-P1740

RGD peptide (GRGDNP)	Integrin Apoptosis	Inflammation/Immunology
RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. RGD peptide (GRGDNP) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.

HY-P1366A

des-Gln14-Ghrelin TFA	Peptides	Metabolic Disease
des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca²⁺]i in CHO-GHSR62 cells, with an EC₅₀ of 2.4 nM.

HY-P1846A

Jagged-1 (188-204) (TFA)	Notch	Cancer
Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.

HY-P1297A

CRF(6-33)(human) TFA	CRFR	Neurological Disease
CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect.

HY-P1022

Kisspeptin-54(human) Metastin(human)	GNRH Receptor	Cancer Endocrinology
Kisspeptin-54(human) (Metastin(human)) is an endogenous ligand for kisspeptin receptor (KISS1, GPR54). Kisspeptin-54(human) binds to rat and human GPR54 receptors with K_i values of 1.81 nM and 1.45 nM, respectively. Kisspeptin-54(human) hinders tumor metastasis and stimulates gonadotropin secretion.

HY-P1306

Obestatin(rat)	GHSR	Inflammation/Immunology Cardiovascular Disease
Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) has anti-inflammatory, anti-myocardial infarction and antioxidant activities.

HY-P1740A

RGD peptide (GRGDNP) (TFA)	Integrin Apoptosis	Inflammation/Immunology Cancer
RGD peptide (GRGDNP) (TFA) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.

HY-P1525

Melanin Concentrating Hormone, salmon MCH (salmon)	MCHR1 (GPR24)	Metabolic Disease Neurological Disease Cardiovascular Disease Endocrinology
Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.

HY-P1039A

R18 TFA PHCVPRDLSWLDLEANMCLP TFA	Peptides	Cancer
R18 TFA is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1.

HY-P1306A

Obestatin(rat) TFA	GHSR	Inflammation/Immunology Cardiovascular Disease
Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) TFA has anti-inflammatory, anti-myocardial infarction and antioxidant activities.

HY-P9900

Human IgG1 Control	Peptides	Others
Human IgG1 Control is purified from normal human serum through Protein G chromatography. Human IgG1 Control can be used as control, standard, blocking agent, or coating protein in a variety of assays, including ELISA, immunobloting (Western and Dot blots), immunoprecipitation, immunodiffusion, and immunoelectrophoresis. Human IgG1 Control may also be used as antigen or ligand in immunochemical conjugation reactions.

HY-P1525A

Melanin Concentrating Hormone, salmon TFA MCH (salmon) (TFA)	MCHR1 (GPR24)	Metabolic Disease Neurological Disease Cardiovascular Disease Endocrinology
Melanin Concentrating Hormone, salmon TFA (MCH (salmon) TFA) is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.

HY-P1022A

Kisspeptin-54(human) TFA Metastin(human) TFA	GNRH Receptor	Cancer Endocrinology
Kisspeptin-54(human) TFA (Metastin(human) TFA) is an endogenous ligand for kisspeptin receptor (KISS1, GPR54). Kisspeptin-54(human) TFA binds to rat and human GPR54 receptors with K_i values of 1.81 nM and 1.45 nM, respectively. Kisspeptin-54(human) TFA hinders tumor metastasis and stimulates gonadotropin secretion.

HY-P2288

WL47	Peptides	Cancer
WL47 is a selective, high-affinity, disrupter of cavolin-1 oligomers (K_d=23 nM) than BSA, casein, and HEWL. WL47 is a caveolin-1 (CAV1) ligand and is 80% smaller in length than the original T20 (HY-P0052) parent sequence. WL47 can be used for the study of caveolin-1 function.

HY-P2036

FSL-1	Toll-like Receptor (TLR) Antibiotic	Infection
FSL-1 is a TLR2/6 agonist (also a putative TLR10 ligand). FSL-1 activates NF-κB. FSL-1 induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. FSL-1 synergizes with IFNγ to induce CXCL10 release from melanoma cells.

HY-P1204

[Ala17]-MCH	MCHR1 (GPR24)	Metabolic Disease
[Ala17]-MCH, a MCH analogue (HY-P1525A), is a selective ligand for MCHR₁ (K_i=0.16 nM) over MCHR₂ (K_i=34 nM). [Eu³⁺ chelate-labeled [Ala17]-MCH shows high affnity for MCHR₁ (K_d=0.37 nM) while has little demonstrable binding affnity for MCHR₂.

HY-P1204A

[Ala17]-MCH TFA	MCHR1 (GPR24)	Metabolic Disease
[Ala17]-MCH TFA, a MCH analogue (HY-P1525A), is a selective ligand for MCHR₁ (K_i=0.16 nM) over MCHR₂ (K_i=34 nM). [Eu³⁺ chelate-labeled [Ala17]-MCH shows high affnity for MCHR₁ (K_d=0.37 nM) while has little demonstrable binding affnity for MCHR₂.

HY-P2036A

FSL-1 TFA	Toll-like Receptor (TLR) Antibiotic	Infection
FSL-1 TFA is a TLR2/6 agonist (also a putative TLR10 ligand). FSL-1 TFA activates NF-κB. FSL-1 TFA induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. FSL-1 TFA synergizes with IFNγ to induce CXCL10 release from melanoma cells.

HY-P0172A

ATI-2341 TFA	CXCR	Cancer Inflammation/Immunology Endocrinology
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).

HY-P0172

ATI-2341	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).

HY-P1320A

[Nphe1]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent.

HY-P1320

[Nphe1]Nociceptin(1-13)NH2	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent.

Cat. No.	Product Name	Target	Research Area

HY-P9904

Atezolizumab
MPDL3280A
PD-1/PD-L1 Cancer

Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P9920

Ramucirumab	VEGFR	Cancer
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.

HY-P9900

Human IgG1 Control	Inhibitory Antibodies	Others
Human IgG1 Control is purified from normal human serum through Protein G chromatography. Human IgG1 Control can be used as control, standard, blocking agent, or coating protein in a variety of assays, including ELISA, immunobloting (Western and Dot blots), immunoprecipitation, immunodiffusion, and immunoelectrophoresis. Human IgG1 Control may also be used as antigen or ligand in immunochemical conjugation reactions.

Cat. No.	Product Name	Target	Category

HY-W007648

Methyl 3-aminopropanoate hydrochloride β-Alanine methyl ester hydrochloride	Others	Natural Products
Methyl 3-aminopropanoate hydrochloride is prepared by esterification of Β-Alanine (I). Methyl 3-aminopropanoate hydrochloride can be used in the synthesis of bidentate pyridine-acid ligand.

HY-N0927

(-)-Isocorypalmine Tetrahydrocolumbamine; (S)-Tetrahydrocolumbamine	Dopamine Receptor	Alkaloids
(-)-Isocorypalmine (Tetrahydrocolumbamine), isolated from the crude base fraction of Corydalis chaerophylla, is a dopamine receptor ligand. Recombinant CYP719A21 displays strict substrate specificity and high affinity (K_m=4.63 ± 0.71 μM) for (-)-Isocorypalmine.

HY-N5024

Gambogenic acid	Histone Methyltransferase	Quinones
Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination.

HY-B0163

Detomidine	Adrenergic Receptor	Alkaloids
Detomidine produce dose-dependent sedative and analgesic effects, is a nonnarcotic, synthetic α2-adrenergic agonist Target: α2-adrenergic agonist Detomidine is an imidazole derivative and α2-adrenergic agonist, used as a large animal sedative, primarily used in horses.

HY-B0225

L-(-)-α-Methyldopa MK-351; Methyldopa	Adrenergic Receptor	Natural Products
Methyldopa is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a sympatholytic or antihypertensive.

HY-B0098

Doxazosin
UK 33274
Adrenergic Receptor Alkaloids

Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-B0447A

L-Epinephrine Bitartrate (-)-Epinephrine (+)-bitartrate salt; L-Adrenaline (+)-bitartrate salt	Adrenergic Receptor	Phenols
L-Epinephrine bitartrate is an *α-adrenergic* and *β-adrenergic* receptor agonist. L-Epinephrine is a hormone secreted by the medulla of the adrenal glands.

HY-B0459

Scopine 6,7-Epoxytropine	Adrenergic Receptor	Alkaloids
Scopine is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.

HY-N0132A

Synephrine hydrochloride Oxedrine hydrochloride	Adrenergic Receptor Endogenous Metabolite	Alkaloids
Synephrine hydrochloride (Oxedrine hydrochloride) is an *α-adrenergic* and *β-adrenergic* agonist derived from the Citrus aurantium, it has sympathomimetic and structural similarities to ephedra and ephedrine alkaloids.

HY-N0132

Synephrine Oxedrine	Adrenergic Receptor Endogenous Metabolite	Alkaloids
Synephrine (Oxedrine) is an *α-adrenergic* and *β-adrenergic* agonist derived from the Citrus aurantium, it has sympathomimetic and structural similarities to ephedra and ephedrine alkaloids.

HY-A0027

Fenspiride Hydrochloride
Adrenergic Receptor Histamine Receptor Alkaloids

Fenspiride Hcl is an α adrenergic and H1 histamine receptor antagonist.

HY-12710A

Rauwolscine hydrochloride α-Yohimbine hydrochloride; Corynanthidine hydrochloride; Isoyohimbine hydrochloride	Adrenergic Receptor	Alkaloids
Rauwolscine hydrochloride is a potent and specific α2 adrenergic receptor antagonist with a K_i of 12 nM.

HY-B0468

Isoprenaline hydrochloride Isoproterenol hydrochloride	Adrenergic Receptor Endogenous Metabolite	Natural Products
Isoprenaline hydrochloride is a non-selective *beta-adrenergic* receptor** agonist with potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities.

HY-113962

7α,25-Dihydroxycholesterol 7α,25-OHC	EBI2/GPR183 Endogenous Metabolite	Steroids
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC₅₀=140 pM; K_d=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells.

HY-13715

Norepinephrine Levarterenol; L-Noradrenaline	Endogenous Metabolite Adrenergic Receptor Autophagy	Phenols
Norepinephrine (Levarterenol; L-Noradrenaline) is a β₁-selective adrenergic receptor agonist with EC₅₀ of 5.37 μM.

HY-B0193

Prazosin
Adrenergic Receptor Alkaloids

Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder.

HY-B0528A

Octopamine hydrochloride (±)-p-Octopamine hydrochlorid	Adrenergic Receptor Endogenous Metabolite	Phenols
Octopamine hydrochloride ((±)-p-Octopamine hydrochlorid) is an endogenous biogenic amine that is closely related to norepinephrine, and has effects on the adrenergic and dopaminergic systems.

HY-113356

m-Tyramine
Endogenous Metabolite Natural Products

m-Tyramine is an endogenous trace amine neuromodulator. m-Tyramine has effects on the adrenergic and dopaminergic receptor^{[1, 2]}.

HY-N0761

Isoferulic acid 3-Hydroxy-4-methoxycinnamic acid	Adrenergic Receptor Influenza Virus	Phenylpropanoids
Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is a cinnamic acid derivative that has antidiabetic activity. Isoferulic acid binds to and activates α1-adrenergic receptors (IC₅₀=1.4 µM) to enhance secretion of β-endorphin (EC₅₀=52.2 nM) and increase glucose use. Isoferulic acid also has anti-influenza virus activities.

HY-N1427A

Glycodeoxycholic acid monohydrate
Others Acids and Aldehydes

Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.
HY-113413

Imidazoleacetic acid
Imidazolyl-4-acetic acid
Endogenous Metabolite Natural Products

Imidazoleacetic acid is an endogenous ligand that stimulates imidazole receptors.

HY-13715B

Norepinephrine bitartrate monohydrate Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate	Adrenergic Receptor Autophagy	Natural Products
Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate) is a β₁-selective adrenergic receptor agonist with EC₅₀ of 5.37 μM.

HY-N0166

Gramine Donaxine	Adiponectin Receptor Adrenergic Receptor Reverse Transcriptase	Alkaloids
Gramine (Donaxine) is a natural alkaloid isolated from giant reed, acts as an active adiponectin receptor (AdipoR) agonist, with IC₅₀s of 3.2 and 4.2 µM for AdipoR2 and AdipoR1, respectively. Gramine is also a human and mouse β2-Adrenergic receptor (β2-AR) agonist. Gramine (Donaxine) has anti-tumor, anti-viral and anti-inflammatory properties.

HY-100583

(-)-(S)-Equol
Estrogen Receptor/ERR Endogenous Metabolite Phenols

(-)-(S)-Equol is a high affinity ligand for estrogen receptor β with a K_i of 0.73 nM.
HY-W011051

2-Arachidonoylglycerol
Cannabinoid Receptor Endogenous Metabolite Natural Products

2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
HY-110399

Cirsiliol
Lipoxygenase Flavonoids

Cirsiliol is a potent and selective 5-lipoxygenase inhibitor and a competitive low affinity benzodiazepine receptor ligand.
HY-N0277

Aconine
Jesaconine
NF-κB Alkaloids

Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.

HY-N2388

Auraptene	MMP	Phenylpropanoids
Auraptene is the most abundant naturally occurring geranyloxycoumarin. Auraptene is primarily isolated from plants in the Rutaceae family, such as citrus fruits. Auraptene decreases the secretion of matrix metalloproteinase 2 (MMP-2) as well as key inflammatory mediators, including IL-6, IL-8, and chemokine (C-C motif) ligand-5(CCL5).

HY-P0260

p2Ca
Others Natural Products

p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.

HY-110385

cGAMP disodium Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium	Endogenous Metabolite	Acids and Aldehydes
cGAMP disodium (Cyclic GMP-AMP disodium) is the third cyclic dinucleotide (CDN) to be discovered in bacteria. cGAMP disodium is an effective adjuvant for sublingual vaccination capable of promoting broad immunity including serum anti-PA neutralizing and anti-PA SIgA responses in airway secretions.

HY-34544

2-Hexylthiophene	Others	Natural Products
2-Hexylthiophene is an extremely weak basic heteroaromatic compound. 2-Hexylthiophene can be used to modify and improve the molar absorption coefficient of ruthenium sensitizer

HY-N4194

Glabrone
PPAR Flavonoids

Glabrone is an isoflavone isolated from Glycyrrhiza glabra roots. Glabrone exhibits anti-influenza activity and significant PPAR-γ ligand-binding activity.

HY-13956

Pioglitazone U 72107	PPAR Ferroptosis	Alkaloids
Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-A0019

Paliperidone 9-Hydroxyrisperidone	Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Natural Products
Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia.

HY-N6253

Pinoresinol (+)-Pinoresinol	Apoptosis	Natural Products
Pinoresinol is a lignol of plant origin serving for defense in a caterpillar. Pinoresinol drastically sensitizes cancer cells against TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis.

HY-108496

Sphingosine-1-phosphate S1P	Endogenous Metabolite LPL Receptor	Saccharides and Glycosides
Sphingosine-1-phosphate (S1P) is an agonist of S1P_1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca²⁺ as an extracellular ligand for G protein-coupled receptors. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids.

HY-22024

5-Hydroxyflavone
Others Flavonoids

5-Hydroxyflavone, a flavonoid ligand, shows no cytotoxic activity against MCF-7, FaDU, MDA-MB-435S, U87, RPE-1, and HEK293 cells.

HY-N0499

Cyanidin Chloride IdB 1027	Others	Natural Products
Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression.

HY-N2078

Yamogenin Neodiosgenin	LXR	Terpenoids and Glycosides
Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes.

HY-N0368

Linalool	iGluR Apoptosis Endogenous Metabolite	Terpenoids and Glycosides
Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity.Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome.

HY-N0443

N-Methylcytisine Caulophylline	nAChR	Alkaloids
N-Methylcytisine (Caulophylline), a tricyclic quinolizidine alkaloid, exerts hypoglycaemic, analgesic and anti-inflammatory activities. N-methylcytisine is a selective ligand of nicotinic receptors of acetylcholine in the central nervous system and has a high affinity (K_d = 50 nM) to nicotinic acetylcholine receptors (nAChR) from squid optical ganglia.

HY-118482

Sauristolactam Saurolactam	Others	Alkaloids
Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells. Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation.

HY-N2025

Oroxin A	PARP Glucosidase	Flavonoids Saccharides and Glycosides
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE), activates peroxisome proliferator-activated receptor γ (PPARγ) by docking into the PPARγ protein ligand-binding domain. Oroxin A exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.

HY-N2453

Convallatoxin	PPAR NF-κB P-glycoprotein	Steroids
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties.

HY-119109

Laminaran	Others	Saccharides and Glycosides
Laminaran is a neutral water-soluble β-1-3-glucan and a typical ligand for Dectin-1 isolated from the brown alga D. dichotoma, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Cat. No.	Product Name	Species	Source

HY-P7111

*Recombinant Human Fms-related Tyrosine Kinase 3 Ligand* (CHO-expressed)** rHuFlt-3 Ligand; Flt3 Ligand; FL; SL cytokine; Flt-3L	Human	CHO
Recombinant Human Fms-related Tyrosine Kinase 3 Ligand (CHO-expressed) is a cytokine, which can promote the generation and differentiation of hematopoietic stem cells and their progenitor cells.

HY-P7354

*Recombinant Mouse Flt-3 Ligand, His (CHO-expressed)* rMuFlt-3 Ligand, His; Fms-related tyrosine kinase 3 Ligand; SL cytokine; Flt3lg	Mouse	CHO
Recombinant Mouse Flt-3 Ligand, His (CHO-expressed) is a ligand of mouse Flt-3, induces proliferation of haematopoietic progenitor cells.

HY-P7319

*Recombinant Mouse Activation-inducible TNF-related Ligand/AITRL* rMuActivation-inducible TNF-related Ligand/AITRL; TNFSF18; GITRL; TL-6	Mouse	E. coli
Recombinant Mouse Activation-inducible TNF-related Ligand/AITRL is a single non-glycosylated polypeptide chain produced in E. coli, with a molecular mass of 14.5 kDa.

HY-P7318

*Recombinant Human Activation-inducible TNF-related Ligand/AITRL* rHuActivation-inducible TNF-related Ligand/AITRL; TNFSF18; GITRL; TL-6; rHuAITRL	Human	E. coli
Recombinant Human Activation-inducible TNF-related Ligand/AITRL is a single non-glycosylated polypeptide chain produced in E. coli, with a molecular mass of 14.3 kDa.

HY-P7446

*Recombinant Mouse 4-1BB Ligand/TNFSF9, His (HEK293-expressed)* rMu4-1BB Ligand/TNFSF9, His; 4-1BBL; CD137L; 4-1BB Ligand; TNFSF9	Mouse	HEK 293
Recombinant Mouse 4-1BB Ligand/TNFSF9, His (HEK293-expressed) is a member of the tumor necrosis factor (TNF) superfamily and is the ligand for the TNFR superfamily receptor 4-1BB, with an N-terminal His tag^[1].

HY-P7398

Recombinant Human PD-L1, His (HEK293-expressed) rHuPD-L1, His; Programmed death Ligand 1; CD274; B7-H1	Human	HEK 293
Recombinant Human PD-L1, His (HEK293-expressed) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P7397

Recombinant Human PD-L1, Fc Chimera (CHO-expressed) rHuPD-L1, Fc Chimera; Programmed death Ligand 1; CD274; B7-H1	Human	CHO
Recombinant Human PD-L1, Fc Chimera (CHO-expressed) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P7412

Recombinant Rat Thrombopoietin, His (CHO-expressed) rRtThpo, His; C-mpl Ligand; MGDF	Rat	CHO
Recombinant Rat Thrombopoietin, His (CHO-expressed) produced in CHO cells is a recombinant rat thrombopoietin (TPO) with his tag. Recombinant Rat Thrombopoietin is a master cytokine regulator of megakaryopoiesis.

HY-P7413

Recombinant Mouse Thrombopoietin, His (HEK293-expressed) rMuThpo, His; C-mpl Ligand; MGDF	Mouse	HEK 293
Recombinant Mouse Thrombopoietin, His (HEK293-expressed) produced in HEK293 cells is a recombinant mouse thrombopoietin (TPO) with his tag produced in HEK293 cells. Recombinant Mouse Thrombopoietin is a major regulator of growth and differentiation of megakaryocytes.

HY-P7399

Recombinant Human PD-L2, Fc Chimera (HEK293-expressed) rHuPD-L2, Fc Chimera; Programmed cell death 1 Ligand 2; B7DC; CD273	Human	HEK 293
Recombinant Human PD-L2, Fc Chimera (HEK293-expressed), a second ligand for PD-1, interacts with PD-1 negatively regulates T cell proliferation, cytokine production and cytotoxic activity.

HY-P7113

*Recombinant Human 4-1BB Ligand/TNFSF9* rHu4-1BBL/TNFSF9; CD137L	Human	E. coli
Recombinant Human 4-1BB Ligand/TNFSF9 is a costimulatory member of the TNF family, which are expressed on activated B cells, macrophages, and dendritic cells.

HY-P7144

Recombinant Human CD40 Ligand rHuCD40L; CD154; TRAP; TNFSF5; CD40LG; CD40-L	Human	E. coli
Recombinant Human CD40 Ligand exerts an important role in immune system regulation, including myeloid progenitor cell development.

HY-P7307

*Recombinant Human Tumor necrosis factor-related apoptosis-inducing ligand* Receptor-2/TNFRSF10B (HEK293-expressed)** rHuTRAILR-2/TNFRSF10B; CD262; DR5; KILLER	Human	HEK 293
Recombinant Human Tumor necrosis factor-related apoptosis-inducing ligand Receptor-2/TNFRSF10B (HEK293-expressed) is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis.

Search Result

Inhibitors & Agonists

Screening Libraries

Dye Reagents

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Natural
Products